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1 Abstract
2 Although blood pressure (BP) control is a major goal in chronic kidney disease (CKD), no 
3 worldwide overview of either its achievement or antihypertensive prescriptions is currently 
4 available. We compared crude prevalence of uncontrolled BP among 17 cohort studies, 
5 including 34 602 individuals with eGFR <60 ml/min/1.73m² and treated hypertension across 4 
6 continents, and estimated observed to expected prevalence ratios (PR), adjusted for 
7 potential confounders. Crude prevalence of BP ≥140/90 mm Hg varied from 28% to 61% and 
8 of BP ≥130/80 from 54% to 84%. Adjusted PR indicated poorer hypertension control than 
9 expected in cohorts from European countries, India, and Uruguay, and better control in those 
10 from North American and high-income Asian countries. Four antihypertensive drug classes 
11 or more were prescribed to more than 30% of participants in North American and some 
12 European cohorts, but this practice was less common elsewhere. RAAS inhibitors were the 
13 most common antihypertensive drugs, prescribed for 54% to 91% of cohort participants. 
14 Differences for other drug classes were much stronger, ranging from 11% to 79% for 
15 diuretics, 22% to 70% for beta-blockers, and 27% to 75% for calcium-channel blockers. The 
16 confounders studied explain only a part of the international variation in BP control among 
17 individuals with CKD. The considerable heterogeneity in prescription patterns worldwide calls 
18 for further investigation into the impact of different approaches on patient outcomes.
19
20 Keywords: chronic kidney disease, hypertension control, antihypertensive treatment, 
21 international health
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1 Introduction
2 Arterial hypertension is prevalent in chronic kidney disease (CKD) and contributes to 
3 its adverse outcomes.1 The major benefits of lowering blood pressure (BP) for survival and 
4 cardiovascular outcomes are well established, as are those of inhibiting the renin 
5 angiotensin-aldosterone system (RAAS) to slow CKD progression.2–8 BP control and RAAS 
6 inhibitor use are therefore major goals in the management of patients with CKD,9 although no 
7 consensus exists about the ideal BP level. Current guidelines agree on a systolic/diastolic BP 
8 target of less than 140/90 mm Hg in CKD patients without diabetes and albuminuria, but 
9 whether lower levels should be recommended for those with these conditions remains 
10 controversial.9–15 Results from the SPRINT trial4 and from recent meta-analyses5,16 suggest 
11 that patients with a broad spectrum of comorbidities, including CKD, may benefit from 
12 systolic BP as low as 120 mm Hg. At the same time, there is concern about adverse effects 
13 from aggressive BP lowering in frail or elderly individuals, and higher BP targets are 
14 therefore considered for this population.9,14 Information about current practices in BP control 
15 and antihypertensive therapy in CKD worldwide remains sparse.
16 Several studies have reported poor BP control in CKD with an apparent two-fold 
17 variability across countries. Prevalence of uncontrolled hypertension above 140/90 mm Hg in 
18 individuals with CKD ranges from near 35% in South Korea17 and the US18,19 to more than 
19 70% in Turkey20; that of BP above 130/80 mm Hg varies from 55% to 65% in the US,18,19 
20 65% in the UK,21 75% in Germany,22 80% in Japan,23 and close to 90% in China.24,25 Some 
21 sources of these variations among different populations may include CKD severity, 
22 prevalence of risk factors, and patterns of antihypertensive treatment. Better understanding 
23 of these would help define priorities for prevention and identify best practices in BP 
24 management.
25 The international Network of Chronic Kidney Disease (iNET-CKD) cohort studies is an 
26 open network of independently funded CKD cohort studies. Endorsed by the International 
27 Society of Nephrology, it was established to promote collaborative research, foster exchange 
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1 of expertise, and create opportunities for research training.26 We used data from these 
2 cohorts to conduct international comparisons of the prevalence of uncontrolled BP in adults 
3 with CKD before and after adjustment for well-known risk factors for poor hypertension 
4 control. We also describe patterns of antihypertensive therapy prescription by study cohort 
5 and world region.
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1 Results
2 Participant characteristics by study
3 Analysis included 34 602 participants from 17 studies. Table 1 presents the participants’ 
4 characteristics by study. They were mainly elderly, with median age mostly exceeding 60 
5 years. Participants were more often men, except in the Australian CKD-QLD and the 
6 CKDopps Brazil, in which the sex ratios approached 1:1 and in the European PROVALID 
7 and RRID, both of which included general practice (GP) patients, predominantly women. 
8 Other study variables were more heterogeneous. For instance, prevalence of moderate and 
9 severe albuminuria (KDIGO A2 or A3) varied widely across cohorts, from 20% in the incident 
10 Uruguayan NRHP to 91% in the Japanese CKD-JAC.
11 Mean blood pressure and prevalence of uncontrolled hypertension by study
12 Mean systolic BP differed by 15 mm Hg between the lowest (Korean KNOW-CKD) and 
13 highest (French CKD-REIN) values in the cohorts we analyzed (Table 2). Likewise, a 12-
14 mm Hg-variation in mean diastolic BP was observed between the lowest (Canadian 
15 CanPREDDICT) and highest (Indian CKD) values. In contrast, standard deviations for both 
16 measures were homogeneous across studies. The higher the BP threshold, the larger the 
17 variation in prevalence of uncontrolled hypertension. Overall, the prevalence of uncontrolled 
18 BP was lower in cohorts from high-income Asian and North American countries, and higher 
19 in nephrology cohorts from Europe.
20 Prevalence ratios of uncontrolled hypertension
21 Ratios of observed to expected prevalence rates of uncontrolled hypertension were not 
22 substantially affected by adjustment for age, gender, diabetes, and eGFR, regardless of BP 
23 threshold (Figure 1A and Tables S1 and S2). In contrast, further adjustment for history of 
24 cardiovascular disease, BMI, and most importantly for albuminuria (Figure 1B) increased the 
25 prevalence ratios of BP ≥140/90 mm Hg in the ICKD and NRHP incident cohorts (from +11% 
26 to +26% and +10% to +23%, respectively), while in CKD-REIN it decreased from +39% to 
27 +29%. In the UK RRID study and the Thai CORE-CKD, prevalence ratios of BP ≥140/90 
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1 mm Hg became close to one and were no longer significant after adjustment. In the final and 
2 most complex adjustment model (further including education level and current smoking, 
3 Figure 1C), this prevalence ratio was highest in the ICKD cohort and in most of the European 
4 studies. Results were similar for BP ≥130/80 mm Hg, but for BP ≥150/90 mm Hg in 
5 individuals aged 60 years or over, prevalence ratio in the German CKD study notably 
6 exceeded those from other studies (+54%, Table S3). Consistently, prevalence ratios of 
7 uncontrolled hypertension (regardless of threshold or adjustment model) were significantly 
8 lower than 1 in cohorts from North America, high-income Asia (KNOW-CKD, CKD-JAC), and 
9 Australia. Meta-regression analyses showed that adjusted prevalence ratios of BP ≥140/90 
10 mm Hg were not associated with either the year at study start (R² 5.6%, p=0.13, Figure 2) or 
11 the type of BP measurement (R² 0.0%, p= 0.67). Adjusted odds ratios for uncontrolled 
12 hypertension associated with known risk factors were similar between BP ≥130/80 and 
13 ≥140/90 mm Hg (Tables S4 and S5). Except for albuminuria and education, they tended to 
14 be non-significant for BP ≥150/90 mm Hg in individuals aged 60 or over (Table S6). 
15 Antihypertensive drugs prescribed
16 The number of antihypertensive drug classes was highest in the cohorts from North America, 
17 where more than 50% of individuals had 3 drug classes or more (Figure 3). This number was 
18 also high in German cohorts (CKDopps and GCKD), PROVALID, and CKDopps Brazil. 
19 CSTRIDE and NRHP (both incident and prevalent) cohorts had the fewest antihypertensive 
20 drug classes: nearly 40% of participants had only one drug class. The most prescribed drug 
21 class was that of RAAS inhibitors (Figure 4). Its frequency ranged from 54% in CKDopps US 
22 to 91% in KNOW-CKD. Diuretics were more frequently prescribed to participants from 
23 CKDopps Brazil (about 80%), and from European (52 to 78%) and North American cohorts 
24 (66 to 74%). Conversely, their frequency was particularly low in Asian cohorts, especially 
25 CSTRIDE (11%). Specifically, the use of mineralocorticoid receptor antagonists in cohorts 
26 with available information ranged from <1% in ICKD to 9% in CKDopps-BR (Table S7). Asian 
27 cohorts stood out for their high frequency of calcium-channel blockers (53 to 75%). Beta-
28 blocker prescription ranged from 22% in CKD-JAC to 70% in CKDopps Germany, and that of 
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1 other antihypertensive drug classes, from 2% in incident NRHP to 41% in CKDopps US. 
2 RAAS inhibitors were the drug class most frequently chosen for single-agent therapy (Table 
3 3, Tables S8.1 to S8.17). Overall, RAAS inhibitors were more often associated with diuretics, 
4 followed by calcium-channel blockers and beta-blockers at equal rates.
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1 Discussion
2 This study confirms the overall inadequate achievement of BP control in patients with 
3 moderate and advanced CKD worldwide, but highlights large international variations that are 
4 only partly explained by patient characteristics. The main novelty of the study is to show how 
5 heterogeneous prescription patterns were across world regions, both in terms of the number 
6 and types of antihypertensive drug classes, with the exception of RAAS inhibitors, which are 
7 commonly prescribed as first-line treatment in all countries. Our finding that cohorts with the 
8 highest number of prescribed antihypertensive drug classes also had the lowest prevalence 
9 rates of uncontrolled BP ≥ 140/90 points out room for improvement in many countries. 
10 Nonetheless, the remaining prevalence of uncontrolled BP ≥ 130/80 mm Hg above 50% in all 
11 cohorts suggests that so low a BP target is unlikely to be achieved. 
12 Disparities in BP levels,27 as well as in hypertension prevalence and control,28–30 have 
13 been extensively described in the general population. The most recent large report about 
14 international variation in BP is that from the Non-Communicable Diseases Risk Factor 
15 Collaboration.27 Age-standardized prevalence of high BP (≥140/90 mm Hg) in that study 
16 tended to be higher in Africa, South and Southeast Asia, Europe, and South America than in 
17 Australia-New Zealand, high-income Asia, or North America. Likewise, hypertension control 
18 was shown to vary considerably across world regions in a systematic analysis including 
19 population-based data: only 26% of people receiving antihypertensive medication in low-and 
20 middle-income countries had BP <140/90 mm Hg, versus 50% of those in high-income 
21 countries.28 To the best of our knowledge, three studies have analyzed international BP data 
22 in CKD; two of them were part of the Dialysis Outcomes and Practice Patterns Study 
23 (DOPPS) in individuals undergoing hemodialysis.31,32 Crude comparisons showed predialysis 
24 BP was lower in participants from Australia, New Zealand, and Europe (44% had BP <140/90 
25 mm Hg) than in those from North America (32%) and Japan (26%).31 An analysis including 
26 patients from 7 European countries found geographical variations in BP that appeared to be 
27 partly explained by latitude.32 In that study, participants from northern countries had higher 
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1 BP levels than those in southern ones, with an increase of 5.1 and 4.4 mm Hg in systolic and 
2 diastolic BP, respectively, for each 10° increase in latitude, independent of patient 
3 characteristics and baseline dialysis prescription. More recently, a study from the 
4 International Database of Ambulatory BP in Renal Patients (I-DARE) collaborative group 
5 showed wide variations in 24-hour BP profiles in patients with nondialysis CKD from 7 
6 studies in 4 countries.33 Like ours, that study showed poor BP control in European cohorts, 
7 either according to clinic BP or to combined clinic and ambulatory BP. Its finding that 
8 European participants had the highest likelihood of white-coat hypertension suggests that 
9 clinic BP may be particularly overestimated in this population. 
10 Our findings about international variations in office BP control among individuals with 
11 earlier CKD stages (eGFR<60 ml/min/1.72m² not requiring renal replacement therapy) are 
12 more consistent with those reported among the general population27–30 than among 
13 hemodialysis patients.31,32 Hypertension control was poorer in cohorts in Europe, South 
14 America, and India than in those in high-income Asia and North America. Overall, a 
15 substantial portion of study participants had high BP: 28 to 61% ≥140/90 mm Hg and 64 to 
16 84% ≥130/80 mm HgHypertension control may be more difficult to achieve in some specific 
17 groups that are overrepresented among CKD patients, such as the elderly, men, and 
18 individuals with stablished cardiovascular disease or diabetes.10 It may be strongly related to 
19 individuals’ lifestyle, including weight control and smoking status. Furthermore, in patients 
20 with CKD, blood pressure levels are influenced by eGFR and albuminuria level.18,24 In our 
21 study, prevalence of the studied risk factors for uncontrolled hypertension differed greatly 
22 across cohorts. Nevertheless, these differences only partly explained the observed 
23 international variations in hypertension control in moderate to severe CKD. Likewise, the 
24 recruitment period and the type of BP measurement accounted for only a small portion of the 
25 heterogeneity across cohort studies. The adoption of different BP targets in some 
26 populations might contribute in part to this heterogeneity. An analysis by Wolf-Meyer et al. in 
27 the general population30 showed that the gap in hypertension control between North 
28 American and European countries was more pronounced for the BP threshold of 140/90 
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1 mm Hg than for that of 160/95 mm Hg, which was accompanied by a similar trend in 
2 hypertension treatment rates. Interestingly, in our analyses, the higher the target BP, the 
3 higher the variation in hypertension control, a finding that does not support this hypothesis. 
4 Although unstudied characteristics including genetics,34 diet,35 economic level,28 and 
5 public health policies36 certainly contribute to these variations in hypertension control, 
6 patterns of antihypertensive drug prescription in CKD are likely to play an important role in 
7 our findings. Evidence from randomized clinical trials and observational studies indicates that 
8 most CKD patients will require at least 2 antihypertensive agents to achieve adequate 
9 hypertension control.9 In our study, half the participants in cohorts with poor BP control 
10 (prevalence ratios >1) had at most 2 antihypertensive agents (except for participants in 
11 PROVALID and CKDopps DE). In Asian cohorts, the number of antihypertensive drug 
12 classes prescribed was also relatively low, but among them, target BP was more often 
13 achieved in those with more aggressive antihypertensive treatment. This is, however, an 
14 ecological comparison and may be confounded by other factors. 
15 RAAS inhibitors have been consistently recommended as the first-choice drug for 
16 hypertension management in CKD patients, particularly because of its renoprotective effect 
17 via proteinuria reduction.9,13,15 Our results suggest quite good compliance with this 
18 recommendation across all the cohorts we analyzed. The frequency of RAAS inhibitor 
19 prescription was even surprisingly high in some cohorts given their mean eGFR: in CKD-
20 JAC, for example (mean eGFR 26 ml/min/1.73m²), 89% of participants were prescribed 
21 RAAS inhibitors. For similar mean eGFR, the frequency of RAAS inhibitors across study 
22 cohorts fell to values as low as 54%, which is suggestive of underuse in some settings. GFR 
23 decrease and related risk of hyperkalemia or acute kidney injury may cause concern when 
24 prescribing RAAS inhibitors for patients with more severe CKD, since current evidence on 
25 their benefit-risk balance is contradictory.37–39 Furthermore, it has been suggested that the 
26 type of physician (primary care physician versus nephrologist) may have an impact on 
27 adherence to the RAAS inhibition recommendation for CKD patients.40–42
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1 Prescription patterns for other drug classes were heterogeneous. In particular, we 
2 showed that CCB was the second most frequently prescribed drug class in Asian cohorts, 
3 apparently mainly at the expense of diuretics. Some guidelines (either for CKD or 
4 hypertension management) 13,15,43 recommend a specific second drug in antihypertensive 
5 treatment more strongly than others do. 9,44,45 Hence, CCB use is recommended in Japan, 
6 Thailand, and UK, likely because of findings from the ACCOMPLISH trial, in which benazepril 
7 plus amlodipine was associated with better cardiovascular46 and renal47 outcomes than 
8 benazepril plus hydrochlorothiazide. Mineralocorticoid receptor antagonists are of particular 
9 interest in the treatment of resistant hypertension.48 They also have been shown to reduce 
10 BP and proteinuria in adults with CKD in association with RAAS inhibitors, although with 
11 increased risk of hyperkalemia.49 In our study, the prescription of mineralocorticoid receptor 
12 antagonists varied internationally, but was rather uncommon.
13  Most guidelines emphasize individualization of treatment based on comorbidities, 
14 side effects, and other factors including drug availability. The highest prevalence of 
15 cardiovascular disease, including coronary artery disease and congestive heart failure, may 
16 at least partly explain the higher use of beta-block rs in some cohorts. But more subjective 
17 factors, such as prescriber preferences, may play a key role in treatment patterns. An 
18 analysis of national prescribing profiles in hypertension showed that prescription patterns 
19 varied among countries, notably with more frequent use of thiazide diuretics in the UK than in 
20 Norway, Germany, or France, and consumption of alpha-blockers twice as high in Norway 
21 than in any other country studied.50 That study also asked clinical researchers and 
22 professionals in drug regulatory agencies about the possible reasons for these variations. 
23 Although factors such as clinical guidelines, the availability of generic drugs, and cost-
24 awareness were recognized as potential explanatory variables, pharmaceutical marketing 
25 was considered to be the main driver for prescribing choices.
26 Strengths and limitations
27 To our knowledge, this is the first international comparison of hypertension control 
28 and treatment patterns in non-dialysis CKD. We included a large number of CKD patients 
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1 from 17 study cohorts across the world, which was possible because of the use of grouped 
2 information (number of participants with a given profile) for analysis. International 
3 comparisons are often adjusted at most for age and sex. By using logistic regression models, 
4 we were able to adjust analyses for several major risk factors for high BP, including kidney 
5 function and albuminuria, which are critical for determining BP levels in CKD. Moreover, we 
6 had information about the main drug classes in hypertension management in CKD.
7 This study also has limitations. Differences in study design between cohorts such as 
8 recruitment years and setting, and BP measurement procedures are likely to affect 
9 comparisons of hypertension control. The definition of uncontrolled hypertension based on a 
10 single-visit BP, mostly obtained through routine measurements, may have led to 
11 misclassification or even overestimation of its prevalence in some settings. Nevertheless, the 
12 consistent results among cohorts within world regions suggest that this was not a major 
13 source of bias. Most cohorts included individuals under nephrology care and may not be 
14 representative of the overall population with moderate or advanced CKD in their country; 
15 generalization to this population is thus precluded. We performed complete-case analysis, 
16 assuming that covariates were missing completely at random. Although this is a strong 
17 assumption, we believed that multiple imputation with available data would not substantially 
18 improve either efficiency or precision in our models. We did not have complete covariate 
19 information for some of the study cohorts, thus all analyses were not fully adjusted. 
20 Furthermore, adjustment for confounders may not be optimal because of the use of grouped 
21 data. However, this approach facilitated data transfer procedures and increased study 
22 participation. Finally, our comparisons did not consider some relevant factors, particularly 
23 medication adherence. An analysis of the REGARDS study, for example, showed that poor 
24 adherence to antihypertensive treatment among CKD participants was common (about 30%) 
25 and associated with a higher likelihood of uncontrolled hypertension.19
26 Conclusions
27 Worldwide variation in hypertension control in patients with moderate to severe CKD 
28 appears to be only partly explained by individual characteristics. In this study, we highlight a 
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1 considerable heterogeneity in both type and number of antihypertensive drug classes 
2 prescribed. Whether a specific drug combination or a more aggressive treatment is 
3 associated with better kidney and cardiovascular outcomes in real life remains to be 
4 evaluated. The widespread prescription of RAAS inhibitors, which are consistently 
5 recommended in CKD, underscores the role of guidelines in the adoption of best practices. 
6 Further investigation of hypertension management in CKD is needed to bridge the gaps in 
7 current recommendations and improve patient outcomes.
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3 iNET-CKD membership prerequisites have been detailed elsewhere.26 iNET-CKD 
4 includes observational studies with defined objectives, patient-level information, and 
5 prospective data collection, and focuses on individuals with predialysis CKD. The present 
6 analysis consists of baseline data from 17 studies including participants aged ≥18 years, with 
7 eGFR <60 ml/min/1.73m² (neither dialyzed nor transplanted) and treated hypertension (under 
8 antihypertensive drug use). Information about study country, recruitment years, target 
9 population, and prevalence of treated hypertension is summarized in Table S9.
10 Study variables
11 A variable dictionary was sent to each participating cohort study in order to harmonize 
12 data regarding covariate definitions, labeling, and coding (Appendix S1). Glomerular filtration 
13 was estimated with the CKD-EPI51 equation, except in CanPREDDICT and CKD-JAC 
14 studies, in which the MDRD52 equation and the 3-variable Japanese equation 53 were used, 
15 respectively. Albuminuria (or equivalent) was classified according to the Kidney Disease 
16 Improving Global Outcomes (KDIGO) 2012 guideline stages as A1 (normal to mildly 
17 increased), A2 (moderately increased), or A3 (severely increased).9 Body mass index (BMI) 
18 was calculated as weight (Kg) divided by square height (m). Diabetes was defined as serum 
19 fasting glucose ≥7.0 mmol/L (≥126 mg/dl), non-fasting glucose ≥11.1 mmol/l (≥200 mg/dl), 
20 glycated hemoglobin A1c ≥6.5%, or use of glucose-lowering drugs. If such information was 
21 not available, diabetes was identified by self-report or medical records. History of 
22 cardiovascular disease was defined as history of coronary artery disease, prior 
23 revascularization, heart failure, stroke or peripheral vascular disease. Education levels 
24 corresponded to the number of years of formal education reported by the participant at the 
25 baseline visit. Smoking status was dichotomized into current and not current smoking, except 
26 for one study in which participants were classified as ever or never smokers. 
27 Blood pressure control and antihypertensive treatment
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1 BP assessment method for each study is described in Table S9. Most studies (10 of 
2 17) provided an office BP value, while the other provided the mean of 3 BP readings 
3 obtained in compliance with a study protocol. We classified participants’ BP control status 
4 according to three thresholds for systolic and diastolic BP: 130/80 mm Hg, 140/90 mm Hg, 
5 and 150/90 mm Hg, the latter only in participants aged ≥60 years only. Antihypertensive 
6 drugs prescribed were identified by self-report or medical reports and classified into the 
7 following classes: renin-angiotensin-aldosterone system (RAAS) inhibitors, diuretics, 
8 calcium-channel blockers, beta-blockers, and other.
9 Statistical analyses
10 To address the study aims, we asked each study cohort to provide descriptive 
11 statistics regarding participants’ characteristics and antihypertensive drug prescriptions. For 
12 each study, we also asked for three datasets containing grouped information including the 
13 number of participants having a particular profile, and respective number of participants with 
14 uncontrolled BP (one dataset for each BP threshold). This was equivalent to having 
15 individual data for each categorized covariate. Characteristics considered for participant 
16 profiling were age (<65 or ≥ 65 years), gender, diabetes, eGFR (≥ 30 or <30 ml/min/1.73m²), 
17 history of cardiovascular disease, BMI (<30 or ≥30 kg/m²), albuminuria (A1, A2 or A3), 
18 education attainment (<12 or ≥12 years of formal education), and smoking status (current or 
19 not). If 20% or more data was missing for a given variable, this variable was excluded from 
20 the dataset. Any participant with missing information for the remaining variables was 
21 excluded. 
22 Using these data, we described participants’ characteristics and BP control by study, 
23 world region (Asia, Australia, Europe, North America, and South America), and recruitment 
24 setting (nephrology or general practices). Categorical variables were presented as 
25 percentages and continuous variables as means ± standard deviations or medians 
26 (interquartile range). Using mixed logistic regression models with study-specific random 
27 intercepts and participant characteristics as fixed effects, we estimated prevalence ratios of 
28 uncontrolled BP (≥130/80, 140/90, or 150/90 mm Hg) for each cohort study. Prevalence 
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1 ratios correspond to the ratio of the true prevalence of uncontrolled BP for a given study 
2 cohort according to the model (predicted mean), divided by the prevalence that would be 
3 expected for a hypothetical cohort with the same case-mix and an intercept parameter equal 
4 to the population average (marginal mean) 54. The respective 95% confidence intervals were 
5 estimated with bias-corrected bootstrap methods. All adjustment variables were not available 
6 for some of the participating studies, either because they were not collected or because they 
7 were missing for ≥ 20% of participants (Table S10). Thus, we performed three adjustment 
8 models: the first included age, gender, diabetes, and eGFR (4-covariate model); the second 
9 further included albuminuria level, cardiovascular disease, and obesity status (7-covariate 
10 model), and the third one added smoking status and educational level (9-covariate model). 
11 These adjustment models included a different set of studies depending on variable 
12 availability (17, 14, or 10 studies, respectively). To test the era effect and the impact of the 
13 type of BP measurement in prevalence ratio estimates, we performed meta-regressions of 
14 the prevalence ratio of uncontrolled BP ≥140/90 mm Hg obtained with the 4-covariate model 
15 on the first year of recruitment, as a surrogate for year at BP measurement, and on the type 
16 of BP measurement. Antihypertensive drugs were described in terms of number and type of 
17 drug classes. Two-sided significance tests were used and P-values <0.05 were considered 
18 significant. Statistical analyses were performed with SAS 9.4 (SAS Institute Inc, Cary, NC) 
19 and R version 3.5.0.
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Table 1. Patient characteristics by study.


















CKD-JAC 1898 63 (55-70) 34.9 41.8 44.9 29.6 23.2 (21.1-25.8) 16.9 27.2 (18.3-37.4) 9.3 28.2 62.5
CORE-CKD 739 65 (58-70) 34.0 54.3 52.8 21.7 25.7 (23.2-29.1) 6.6 36.6 (28.1-47.4) 30.7 25.4 43.8
CSTRIDE 1305 52 (42-62) 39.2 27.1 29.7 14.1 24.5 (22.0-26.8) 39.9* 32.3 (22.4-43.2) 22.1 23.3 54.6
ICKD 676 50 (41-58) 31.2 45.4 30.9 12.9 24.1 (21.6-27.3) 16.0 39.5 (33.5-47.6) 56.8 17.3 25.9
KNOW-CKD 1313 58 (50-65) 36.3 36.9 34.7 17.4 24.1 (21.6-26.3) 15.3 33.1 (22.6-45.0) 30.4 23.2 46.5
Australia
CKD-QLD 1504 72 (63-79) 47.9 NA 54.3 56.3 30.2 (26.0-35.4) 8.4 34.0 (24.0-42.0) 27.6 31.4 41.0
Europe
CKD-REIN 2147 69 (61-77) 33.5 35.1 44.2 43.1 28.0 (24.9-32.0) 11.9 31.2 (22.9-40.2) 26.8 31.2 42
CKDopps DE 877 75 (67-80) 42.6 NA 43.3 30.7 29.0 (25.5-32.7) NA 26.0 (21.7-32.8) NA NA NA
GCKD 3734 65 (57-70) 36.9 46.8 39.2 34.6 29.3 (26.0-33.5) 14.4 42.0 (34.0-49.0) 43.1 30.8 26.1
PSI BIND-NL 517 63 (52-71) 33.1 78.9 20.1 38.1 27.0 (24.3-30.9) 16.8 30.9 (21.5-43.3) 27.5 21.1 51.5
North America
CanPREDDICT 2411 71 (62-77) 37.4 NA 49.5 57.3 28.7 (25.1-33.2) NA 27.0 (20.1-34.7) 25.5 35.6 38.9
CKDopps US 771 71 (61-78) 45.7 NA 60.7 45.7 31.3 (26.7-37.5) 9.7 25.0 (18.0-33.0) NA NA NA
CRIC 2801 61 (54-67) 44.9 76.5 53.5 38.0 31.3 (27.3-36.5) 13.0 39.8 (31.0-47.9) 35.2 27.5 37.3
South America
CKDopps BR 509 68 (59-77) 49.7 8.8 47.3 44.8 NA 7.3 24.0 (17.0-31.0) 42.8 17.5 24.2
NRHP prevalent 6460 73 (65-79) 41.9 NA 38.9 36.5 28.5 (25.3-32.1) 5.6 35.8 (26.9-44.8) 75.8 10.1 14.0
GP cohorts
NRHP incident 5257 72 (65-79) 43.6 NA 38.4 37.3 28.8 (25.6-32.5) 7.1 38.3 (29.8-46.5) 79.9 9.4 10.7
PROVALID 641 69 (64-79) 57.3 NA 100** 45.6 30.8 (25.2-34.5) 7.8 48.0 (39.4-51.1) 62.7 27.5 9.8
RRID 1042 76 (70-81) 53.4 23.1 22.2 27.0 28.7 (25.9-32.0) 4.1 48.1 (41.6-54.1) 77.4 19.2 3.4
Abbreviations: IQR, interquartile range; CVD, cardiovascular disease; BMI, body mass index; eGFR, estimated glomerular filtration rate; GP: general practice; NA, not available or missing at ≥20%.
*Current or former smoking. **PROVALID included only patients with diabetes.
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Table 2. Mean systolic and diastolic blood pressure (mm Hg), and prevalence of uncontrolled 



















CKD-JAC 132.2 (18.0) 76.6 (11.7) 60.6 32.6 19.9 Study protocol
CORE-CKD 138.9 (18.6) 77.7 (12.0) 73.1 45.5 27.4 Study protocol
CSTRIDE 133.8 (17.6) 82.8 (11.1) 75.8 40.1 24.9 Study protocol
ICKD 135.2 (19.8) 83.2 (10.8) 80.2 47.3 32.7 Study protocol
KNOW-CKD 129.2 (16.8) 76.6 (11.1) 60.5 27.3 17.8 Office BP
Australia
CKD-QLD 133.6 (20.2) 71.4 (11.6) 64.0 38.5 24.1 Office BP
Europe
CKD-REIN 143.9 (20.2) 78.5 (12.2) 83.8 60.9 42.6 Office BP
CKDopps DE 138.5 (16.7) 76.2 (9.9) 79.7 49.5 23.6 Office BP
GCKD 140.6 (20.6) 78.7 (12.0) 75.2 51.0 38.0 Study protocol
PSI BIND-NL 138.9 (19.8) 82.5 (11.7) 77.2 50.1 41.5 Office BP
North America
CanPREDDICT 134.3 (20.0) 70.8 (11.9) 63.6 37.5 23.6 Office BP
CKDopps US 136.6 (20.8) 72.7 (11.8) 66.4 43.5 23.7 Office BP
CRIC 131.0 (22.3) 71.2 (12.9) 54.3 33.9 20.9 Study protocol
South America
CKDopps BR 134.1 (21.0) 79.3 (12.0) 79.2 49.5 32.3 Office BP
NRHP prevalent 133.1 (20.6) 75.7 (12.3) 70.6 43.6 27.9 Office BP
GP cohorts
NRHP incident 134.7 (22.4) 76.0 (12.9) 70.9 46.7 30.2 Office BP
PROVALID 136.4 (20.4) 77.8 (11.8) 81.0 46.6 7.9 Office BP
RRID 134.7 (19.1) 70.9 (11.1) 61.7 37.6 20.2 Study protocol
*Among patients aged 60 years or over.
**See more details about BP measurement methods in Supp Table 1.
Abbreviations: GP, general practice; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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Table 3. Patterns of antihypertensive drug prescription. In the left table, frequency of each antihypertensive drug class is reported according to 
the number of prescribed classes. The right table reports the frequency of two-by-two associations between antihypertensive drug classes. 































66.3% 71.1% 84.2% 93.4% 23.0%, alone 74.1% 68.7% 69.9% 64.9%
Diuretics 9.4% 53.7% 79.1% 91.7% 52.3% 4.6%, alone 56.1% 63.9% 69.1%
CCB 14.2% 35.1% 57.2% 89.3% 38.8% 44.9% 8.7%, alone 47.0% 63.0%
β-blockers 9.3% 32.6% 63.2% 85.0% 38.3% 49.6% 45.6% 5.9%, alone 54.5%
Other 0.9% 4.9% 10.3% 40.1% 8.9% 13.4% 15.2% 13.6% 2.2%, alone
Abbreviations: RAAS inhibitors, renin-angiotensin-aldosterone system inhibitors; CCB, calcium channel blockers.
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Figures
Figure 1A-C. Adjusted prevalence ratios of blood pressure ≥130/80 or ≥140/90 mm Hg by 
study. 
Values above 1 indicate lower frequency of blood pressure control than expected, given 
study patient characteristics. A: Adjusted for age, gender, diabetes status, and eGFR 
category; B: Further adjusted for history of cardiovascular disease, obesity, and albuminuria 
category; C: Further adjusted for education and smoking status. Abbreviations: AU, Australia; 
PR, prevalence ratio; CI, confidence interval; GP, general practice; NA, not available.
Figure 2. Adjusted prevalence ratios of uncontrolled blood pressure ≥140/90 mm Hg 
according to the year at study start, by study. 
Prevalence ratio values above 1 indicate lower frequency of blood pressure control than 
expected, given study patient characteristics. R², β, and p values were estimated with meta-
regression analysis of prevalence ratios of uncontrolled blood pressure ≥140/90 mm Hg 
adjusted for age, gender, diabetes status, and eGFR category on the year at study start, as 
surrogate of year at BP measurement. Abbreviations: PR, prevalence ratio; BP, blood 
pressure; GP, general practice.
Figure 3. Number of antihypertensive drug classes prescribed by study.
Abbreviations: AU, Australia; GP, general practice.
Figure 4. Type of antihypertensive drug classes prescribed by study.
Abbreviations: RAAS, Renin-angiotensin-aldosterone system; GP, general practice.
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1 Abstract
2 Although blood pressure (BP) control is a major goal in chronic kidney disease (CKD), no 
3 worldwide overview of either its achievement or antihypertensive prescriptions is currently 
4 available. We compared crude prevalence of uncontrolled BP among 17 cohort studies, 
5 including 34 602 individuals with eGFR <60 ml/min/1.73m² and treated hypertension across 4 
6 continents, and estimated observed to expected prevalence ratios (PR) for each cohort, 
7 adjusted for potential confounders. Crude prevalence of BP ≥ 140/90 mm Hg varied from 
8 28% to 61% and of BP ≥ 130/80 from 54% to 84%. Adjusted PR indicated poorer 
9 hypertension control than expected in cohorts from European countries, India, and Uruguay, 
10 and better control in those from North American and high-income Asian countries. More than 
11 30% of participants used fFour antihypertensive drug classes or more were prescribed to 
12 more than 30% of participants in North American and some European cohorts, but this 
13 practice was less common elsewhere. RAAS inhibitors were the most common 
14 antihypertensive drugs, prescribed for 54% to 91% of cohort participants. Differences for 
15 other drug classes were much stronger, ranging from 11% to 79% for diuretics, 22% to 70% 
16 for beta-blockers, and 27% to 75% for calcium-channel blockers. The confounders studied 
17 explain only a part of the international variation in BP control among individuals with CKD. 
18 The considerable heterogeneity in prescription patterns worldwide calls for further 
19 investigation into the impact of different approaches on patient outcomes.
20
21 Keywords: chronic kidney disease, hypertension control, antihypertensive treatment, 
22 international health
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1 Introduction
2 Arterial hypertension is highly prevalent in chronic kidney disease (CKD) and 
3 contributes strongly to its adverse outcomes.1 The major benefits of lowering blood pressure 
4 (BP) for survival and cardiovascular outcomes are well established, as are those of inhibiting 
5 the renin angiotensin-aldosterone system (RAAS) to slow CKD progression to end-stage 
6 renal disease (ESRD).2–8 BP control and RAAS inhibitor use are therefore major goals in the 
7 management of patients with CKD,9 although no consensus exists about the ideal BP level. 
8 Current guidelines agree on a systolic/diastolic BP target of less than 140/90 mm Hg in CKD 
9 patients without diabetes and albuminuria, but whether lower levels should be recommended 
10 for those with these conditions remains controversial.9–15 Results from the SPRINT trial4 and 
11 from recent systematic reviews with meta-analyses5,16 suggest that patients with a broad 
12 spectrum of comorbidities, including CKD, may benefit from systolic BP as low as 120 
13 mm Hg. At the same time, there is concern about intolerance and adverse effects from 
14 aggressive BP lowering in frail or elderly individuals, and higher BP targets are therefore 
15 considered for this population.9,14 Information about current practices in BP control and 
16 antihypertensive therapy in CKD worldwide remains sparse.
17 Several studies have reported poor BP control in CKD with an apparent two-fold 
18 variability across countries. Prevalence rates of uncontrolled hypertension above 140/90 
19 mm Hg in individuals with CKD ranges from near 35% in South Korea17 and the US18,19 to 
20 more than 70% in Turkey20; those that of BP above 130/80 mm Hg vary varies from 55% to 
21 65% in the US,18,19 65% in the UK,21 75% in Germany,22 80% in Japan,23 and close to 90% in 
22 China.24,25 Some sources of these variations among different populations may include CKD 
23 severity, prevalence of risk factors, and patterns of antihypertensive treatment. Better 
24 understanding of these would help define priorities for prevention and identify best practices 
25 in BP management.
26 The international Network of Chronic Kidney Disease (iNET-CKD) cohort studies is an 
27 open network of independently funded CKD cohort studies. Endorsed by the International 
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1 Society of Nephrology, it was established to promote collaborative research, foster exchange 
2 of expertise, and create opportunities for research training.26 We used data from these 
3 cohorts to conduct international comparisons of the prevalence of uncontrolled BP in adults 
4 with CKD before and after adjustment for well-known risk factors for poor hypertension 
5 control. We also described patterns of antihypertensive therapy prescription by study cohort 
6 and world region in this population.
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1 Results
2 Participant characteristics by study
3 Analysis included 34 602 participants from 17 studies. Table 1 presents the participants’ 
4 characteristics by study. They were mainly elderly, with median age mostly exceeding 60 
5 years. Participants were more often men, except in the Australian CKD-QLD and the 
6 CKDopps Brazil, in which the sex ratios approached 1:1 and in the European PROVALID 
7 and RRID, both of which included general practice (GP) patients, predominantly women. 
8 Other study variables were more heterogeneous. For instance, The percentage of individuals 
9 with a high educational level (≥12 years of formal education) ranged from 9 to 79%, and 
10 diabetes prevalence from 20 to 100%, depending on the background population or study 
11 design. Median BMI was lowest (23 to 26 kg/m²) in cohort studies from Asia and highest (31 
12 kg/m²) in those from the US. Overall, current smoking was uncommon, except in the Chinese 
13 C-STRIDE cohort where the observed high prevalence may be attributed to the pooling of 
14 current and former smokers. Pprevalence of moderate and severe albuminuria (KDIGO A2 or 
15 A3) varied widely across cohort studies, from 20% in the incident Uruguayan NRHP to 91% 
16 in the Japanese CKD-JAC.
17 Table 1. Patient characteristics by study.
18 Mean blood pressure and prevalence of uncontrolled hypertension by study
19 Mean systolic BP differed by 15 mm Hg between the lowest (Korean KNOW-CKD) and 
20 highest (French CKD-REIN) values in the cohorts we analyzed (Table 2). Likewise, a 12-
21 mm Hg-variation in mean diastolic BP was observed between the lowest (Canadian 
22 CanPREDDICT) and highest (Indian CKD) values. In contrast, standard deviations for both 
23 measures were homogeneous across studies. The higher the BP threshold, the larger the 
24 variation in prevalence of uncontrolled hypertension. Thus the lowest and highest prevalence 
25 rates differed by a factor of 1.4 for BP ≥130/80 mm Hg, by 2.2 for BP ≥140/90 mm Hg, and 
26 by 5.4 for BP ≥150/90 mm Hg in participants, all aged 60 years or older. Overall, the 
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1 prevalence of uncontrolled BP was lower in cohorts from high-income Asian and North 
2 American countries, and higher in nephrology cohorts from Europe.
3 Table 2. Mean systolic and diastolic blood pressure (mm Hg) and prevalence of uncontrolled 
4 hypertension according to blood pressure target, by study.
5 Prevalence ratios of uncontrolled hypertension
6 Ratios of observed to expected prevalence rates of uncontrolled hypertension were not 
7 substantially affected by adjustment for age, gender, diabetes, and eGFR, regardless of BP 
8 threshold (Figure 1A and Supp Tables S31 and S42). In contrast, further adjustment for 
9 history of cardiovascular disease, BMI, and most importantly for albuminuria (Figure 1B) 
10 increased the prevalence ratios of BP ≥140/90 mm Hg in the ICKD and NRHP incident 
11 cohorts (from +11% to +26% and +10% to +23%, respectively), while that in CKD-REIN it 
12 decreased from +39% to +29%. In the UK RRID study and the Thai CORE-CKD, prevalence 
13 ratios of BP ≥140/90 mm Hg became close to one and were no longer significant after 
14 adjustment. In the final and most complex adjustment model (further including education 
15 level and current smoking, Figure 1C), this the prevalence ratio of uncontrolled hypertension 
16 was highest in the ICKD cohort and thenin most of the European studies (CKD-REIN, 
17 German GCKD, and PSI-BIND Netherlands). Results were similar for BP ≥130/80 mm Hg, 
18 but for BP ≥150/90 mm Hg in individuals aged 60 years or over, the GCKD prevalence ratio 
19 in the German CKD study notably exceeded those from other studies (+54%, Supp Table 
20 5S3). Consistently, prevalence ratios of uncontrolled hypertension (regardless of threshold or 
21 adjustment model) were significantly lower than 1 in cohorts from North America (US CRIC 
22 and CKDopps, CanPREDDICT), high-income Asia (KNOW-CKD, CKD-JAC), and Australia 
23 (CKD-QLD). Meta-regression analyses showed that adjusted prevalence ratios of BP 
24 ≥140/90 mm Hg were not associated with either the year at study start (R² 5.6%, p=0.13, 
25 Figure 2) or the type of BP measurement (R² 0.0%, p= 0.67). Adjusted odds ratios for 
26 uncontrolled hypertension associated with known risk factors were quite similar between BP 
27 ≥130/80 and ≥140/90 mm Hg (Supp Tables S46 and S57). Except for albuminuria and 
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1 education, they tended to be non-significant for BP ≥150/90 mm Hg in individuals aged 60 or 
2 over (Supp Table S68). 
3 Figure 1A-C. Adjusted prevalence ratios of blood pressure ≥130/80 or ≥140/90 mm Hg by 
4 study. 
5 Antihypertensive drugs prescribed
6 The number of antihypertensive drug classes prescribed was highest in the cohorts from 
7 North America, where more than 6050% of individuals were usinghad 3 drug classes or more 
8 (Figure 3, Supp Table 9). Notably, 50% of CRIC participants were taking ≥4 drug classes. 
9 This number was also high in German cohorts (CKDopps and GCKD), PROVALID, and 
10 CKDopps Brazil. CSTRIDE and NRHP (both incident and prevalent) cohorts had the lowest 
11 number of fewest antihypertensive drug classes prescribed: nearly 40% of participants took 
12 had only one drug class. The most used prescribed antihypertensive drug class was that of 
13 RAAS inhibitors (Figure 4). Its frequency ranged from 54% in CKDopps US to 91% in 
14 KNOW-CKD. Diuretics were more frequently prescribed to participants from CKDopps Brazil 
15 (about 80%), and from European (52 to 78%) and North American cohorts (66 to 74%). 
16 Conversely, their frequency was particularly low in Asian cohorts, especially CSTRIDE 
17 (11%). Specifically, the use of mineralocorticoid receptor antagonists in cohorts with 
18 available information ranged from <1% in ICKD to 9% in CKDopps-BR (Table S7). Asian 
19 cohorts also stood out for their high use frequency of calcium-channel blockers (53 to 75%). 
20 Beta-blocker use prescription ranged from 22% in CKD-JAC to 70% in CKDopps Germany, 
21 with no evident pattern regarding world region. Wide variation was observed for  and that of 
22 other antihypertensive drug classes, from 2% in incident NRHP to 41% in CKDopps US. 
23 RAAS inhibitors were the drug class most frequently chosen for single-agent therapy, except 
24 in the CRIC study in which no participant received RAAS inhibitors alone (Table 3, Supp 
25 Tables S810.1 to S810.17). Overall, RAAS inhibitors were more often associated with 
26 diuretics, followed by calcium-channel blockers and beta-blockers at equal rates.
27 Figure 2. Number of antihypertensive drug classes prescribed by study.
28 Figure 3. Type of antihypertensive drug classes prescribed by study.
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1 Table 3. Patterns of antihypertensive drug prescription.
Page 37 of 91






























































For Peer Review Only
9
1 Discussion
2 This study confirms the overall inadequate achievement of BP control in patients with 
3 moderate and advanced CKD worldwide, but highlights large international variations that are 
4 only partly explained by individual patient characteristics. The main novelty of the study is to 
5 show how heterogeneous prescription patterns were across world regions, both in terms of 
6 the number and types of antihypertensive drug classes, with the exception of RAAS 
7 inhibitors, which are commonly used prescribed as first-line treatment in all countries. Our 
8 finding that cohorts with the highest number of prescribed antihypertensive drug classes also 
9 had the lowest prevalence rates of uncontrolled BP ≥ 140/90 points out room for 
10 improvement in many countries. Nonetheless, the remaining prevalence of uncontrolled BP ≥ 
11 130/80 mm Hg above 50% in all cohorts in which half the participants use four drug classes  
12 suggests that so low a BP target is unlikely to be achieved. 
13 Disparities in BP levels,27 as well as in hypertension prevalence and control,28–30 have 
14 been extensively described in the general population. The most recent large report about 
15 international variation in BP is that from the Non-Communicable Diseases Risk Factor 
16 Collaboration.27 Age-standardized prevalence of high BP (≥140/90 mm Hg) in that study 
17 tended to be higher in Africa, South and Southeast Asia, Europe, and South America than in 
18 Australia-New Zealand, high-income Asia, or North America, with regional differences more 
19 pronounced in men than women. Likewise, hypertension control was shown to vary 
20 considerably across world regions in a systematic analysis including population-based data: 
21 only 26% of people receiving antihypertensive medication in low-and middle-income 
22 countries had BP <140/90 mm Hg, versus 50% of those in high-income countries.28 To the 
23 best of our knowledge, three studies have analyzed international BP data in CKD; two of 
24 them were part of the Dialysis Outcomes and Practice Patterns Study (DOPPS) and 
25 restricted toin individuals undergoing hemodialysis.31,32 Crude comparisons showed 
26 predialysis BP was lower in participants from Australia, New Zealand, and Europe (44% had 
27 BP <140/90 mm Hg) than in those from North America (32%) and Japan (26%).31 An analysis 
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1 including patients from 7 European countries found geographical variations in BP that 
2 appeared to be partly explained by latitude.32 In that study, participants from northern 
3 countries had higher BP levels than those in southern ones, with an increase of 5.1 and 4.4 
4 mm Hg in systolic and diastolic BP, respectively, for each 10° increase in latitude, 
5 independent of patient characteristics and baseline dialysis prescription. More recently, a 
6 study from the International Database of Ambulatory BP in Renal Patients (I-DARE) 
7 collaborative group showed wide variations in 24-hour BP profiles in patients with nondialysis 
8 CKD from 7 studies in 4 countriesdifferent countries even after adjusting for age, sex, eGFR 
9 and diabetes.33 Like ours, that study showed poor BP control in European cohorts, either 
10 according to clinic BP or to combined clinic and ambulatory BP. Its finding that European 
11 participants had the highest likelihood of white-coat hypertension suggests that clinic BP may 
12 be particularly overestimated in this population. Compared with CKD-JAC participants, CRIC 
13 study participants were less likely to have masked hypertension, but had similar prevalence 
14 of sustained hypertension, participants in the African American Study of Kidney Disease and 
15 Hypertension Cohort Study (AASK) were more likely to have masked and sustained 
16 hypertension, and those from the Italian and Spanish studies, less likely. 
17 Our findings about international variations in office BP control among individuals with 
18 earlier CKD stages (eGFR<60 ml/min/1.72m² not requiring renal replacement therapy) are 
19 more consistent with those reported among the general population27–30 than among 
20 hemodialysis patients.31,32 Hypertension control was poorer in cohorts in Europe, South 
21 America, and India than in those in high-income Asia and North America. But oOverall, a 
22 substantial portion of study participants had high BP: 28 to 61% ≥140/90 mm Hg and 64 to 
23 84% ≥130/80 mm Hg. Because the composition of the cohorts might well influence BP 
24 control rates, we adjusted analyses for several major risk factors of high BP. Although this 
25 did not change the overall geographical pattern of BP control, adjustment for potential 
26 confounders brought several interesting points to light. For instance, after adjustment, the 
27 observed to expected prevalence of BP ≥140/90 mm Hg increased in cohorts from India 
28 (ICKD) and Uruguay (NRHP), while that from both Thailand (CORE-CKD) and the UK (RRID) 
Page 39 of 91






























































For Peer Review Only
11
1 became close to one. Adjustment also substantially reduced heterogeneity in prevalence 
2 ratios across European cohorts, with albuminuria the most important confounder. 
3 Nonetheless, variation in hypertension control among CKD patients remained largely 
4 unexplained. The adoption of different BP targets in some populations might contribute in 
5 part to these findings. An analysis by Wolf-Meyer et al. in the general population30 showed 
6 that the gap in hypertension control between North American and European countries was 
7 more pronounced for the BP threshold of 140/90 mm Hg than for that of 160/95 mm Hg, 
8 which was accompanied by a similar trend in hypertension treatment rates. Interestingly, in 
9 our analyses, the higher the target BP, the higher the variation in hypertension control, a 
10 finding that does not support this hypothesis. 
11 Hypertension control may be more difficult to achieve in some specific groups that are 
12 overrepresented among CKD patients, such as the elderly, men, and individuals with 
13 stablished cardiovascular disease or diabetes.10 It may be strongly related to individuals’ 
14 lifestyle, including weight control and smoking status. Furthermore, in patients with CKD, 
15 blood pressure levels are influenced by eGFR and albuminuria level.18,24 In our study, 
16 prevalence of the studied risk factors for uncontrolled hypertension differed greatly across 
17 cohorts. Nevertheless, these differences only partly explained the observed international 
18 variations in hypertension control in moderate to severe CKD. Likewise, the recruitment 
19 period and the type of BP measurement accounted for only a small portion of the 
20 heterogeneity across cohort studies. The adoption of different BP targets in some 
21 populations might contribute in part to these this findingsheterogeneity. An analysis by Wolf-
22 Meyer et al. in the general population30 showed that the gap in hypertension control between 
23 North American and European countries was more pronounced for the BP threshold of 
24 140/90 mm Hg than for that of 160/95 mm Hg, which was accompanied by a similar trend in 
25 hypertension treatment rates. Interestingly, in our analyses, the higher the target BP, the 
26 higher the variation in hypertension control, a finding that does not support this hypothesis. 
27 Although unstudied geographical specificities characteristics including genetics,34 
28 diet,35 economic level,28 and public health policies36 certainly contribute to these international 
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1 variations in hypertension control, patterns of antihypertensive drug prescription in CKD are 
2 likely to play an important role in our findings. Evidence from randomized clinical trials and 
3 observational studies indicates that most CKD patients will require at least 2 antihypertensive 
4 agents to achieve adequate hypertension control.9 In our study, a relatively better rate of 
5 hypertension control — around 45% for BP< 130/80 mm Hg in the US CRIC study — was 
6 accompanied by a much more aggressive antihypertensive strategy than in other study 
7 cohorts: 50% of CRIC participants had ≥4 antihypertensive drugs classes prescribed. The 
8 much lower rate of hypertension control at <130/80 mm Hg and the similarly lower number of 
9 antihypertensive drug classes prescribed in CKDopps US suggest the importance of the 
10 study setting (academic centers in the CRIC study versus nonacademic in CKDopps). Half 
11 half the participants in study cohorts with poor BP control (prevalence ratios >1) were using 
12 had at most 2 antihypertensive agents (except for participants in PROVALID and CKDopps 
13 DE). In Asian cohorts, the number of antihypertensive drug classes prescribed was also 
14 relatively low, but among them, target BP was more often achieved in those with higher more 
15 aggressive antihypertensive drug usetreatment. This is, however, an ecological comparison 
16 and may be confounded by other factors. 
17 RAAS inhibitors have been consistently recommended as the first-choice drug for 
18 hypertension management in CKD patients, particularly because of its renoprotective effect 
19 via proteinuria reduction.9,13,15 Our results suggest quite good compliance with this 
20 recommendation across all the cohorts we analyzed. The frequency of RAAS inhibitor use 
21 prescription was even surprisingly high in some cohorts given their mean eGFR: in CKD-
22 JAC, for example (mean eGFR 26 ml/min/1.73m²), 89% of participants used were prescribed 
23 RAAS inhibitors. For similar mean eGFR, the frequency of RAAS inhibitors across study 
24 cohorts fell to values as low as 54%, which is suggestive of underuse in some settings. GFR 
25 decrease and related risk of hyperkalemia or acute kidney injury may cause concern when 
26 prescribing RAAS inhibitors for patients with more severe CKD, since current evidence on 
27 their benefit-risk balance is contradictory.37–39 Furthermore, it has been suggested that the 
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1 type of physician (primary care physician versus nephrologist) may have an impact on 
2 adherence to the RAAS inhibition recommendation for CKD patients.40–42
3 Prescription patterns for other drug classes were heterogeneous. In particular, we 
4 showed that CCB was the second most frequently preferred prescribed drug class in Asian 
5 cohorts, apparently mainly at the expense of diuretics use. Some guidelines (either for CKD 
6 or hypertension management) 13,15,43 recommend a specific second drug in antihypertensive 
7 treatment more strongly than others do. 9,44,45 Hence, CCB use is recommended in Japan, 
8 Thailand, and UK, likely because of findings from the ACCOMPLISH trial, in which benazepril 
9 plus amlodipine was associated with better cardiovascular46 and renal47 outcomes than 
10 benazepril plus hydrochlorothiazide. Mineralocorticoid receptor antagonists are of particular 
11 interest in the treatment of resistant hypertension.48 They also have been shown to reduce 
12 BP and proteinuria in adults with CKD in association with RAAS inhibitors, although with 
13 increased risk of hyperkalemia.49 In our study, the prescription of mineralocorticoid receptor 
14 antagonists varied internationally, but was rather uncommon.
15  Most guidelines emphasize individualization of treatment based on comorbidities, 
16 side effects, and other factors including drug availability. The highest prevalence of 
17 cardiovascular disease, including coronary artery disease and congestive heart failure, may 
18 at least partly explain the higher use of beta-blockers in some cohorts. But more subjective 
19 factors, such as prescriber preferences, may play a key role in treatment patterns. However, 
20 most guidelines emphasize individualization of treatment based on comorbidities, side 
21 effects, and other factors including drug availability and thus leave room for prescriber 
22 preferences. An analysis of national prescribing profiles in hypertension showed that 
23 prescription patterns varied among countries, notably with more frequent use of thiazide 
24 diuretics in the UK than in Norway, Germany, or France, and consumption of alpha-blockers 
25 twice as high in Norway than in any other country studied.50 That study also asked clinical 
26 researchers and professionals in drug regulatory agencies about the possible reasons for 
27 these variations. Although factors such as clinical guidelines, the availability of generic drugs, 
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1 and cost-awareness were recognized as potential explanatory variables, pharmaceutical 
2 marketing was considered to be the main driver for prescribing choices.
3 Strengths and limitations
4 To our knowledge, this is the first international comparison of hypertension control 
5 and treatment patterns in non-dialysis CKD. We included a large number of CKD patients 
6 from 17 study cohorts across the world, which was possible because of the use of grouped 
7 information (number of participants with a given profile) for analysis. International 
8 comparisons are often adjusted at most for age and sex. By using logistic regression models, 
9 we were able to adjust analyses for several major risk factors for high BP, including kidney 
10 function and albuminuria, which are critical for determining BP levels in CKD. Moreover, we 
11 had information about the main drug classes used in hypertension management in CKD.
12 This study also has limitations. First, dDifferences in study design between cohorts 
13 such as recruitment years and setting, and BP measurement procedures are likely to affect 
14 comparisons of hypertension control. The definition of uncontrolled hypertension based on a 
15 single-visit BP, mostly obtained through routine measurements, may have led to 
16 misclassification or even overestimation of its prevalence in some settings. Nevertheless, the 
17 consistent results among cohorts within a world regions suggest that this was not a major 
18 source of bias. Second, mMost cohorts included individuals under nephrology care and may 
19 not be representative of the overall population with moderate or advanced CKD in their 
20 country; generalization to this population is thus precluded. We performed complete-case 
21 analysis, assuming that covariates were missing completely at random. Although this is a 
22 strong assumption, we believed that multiple imputation with available data would not 
23 substantially improve either efficiency or precision in our models.Third, w We did not have 
24 complete covariate information for some of the study cohorts, thus all analyses were not fully 
25 adjusted. Furthermore, adjustment for confounders may not be optimal because of the use of 
26 grouped data. However, this approach facilitated data transfer procedures and increased 
27 study participation. Finally, our comparisons did not consider some relevant factors, 
28 particularly medication adherence. An analysis of the REGARDS study, for example, showed 
Page 43 of 91






























































For Peer Review Only
15
1 that poor adherence to antihypertensive treatment among CKD participants was common 
2 (about 30%) and associated with a higher likelihood of uncontrolled hypertension.19
3 Conclusions
4 Worldwide variation in hypertension control in patients with moderate to severe CKD 
5 appears to be only partly explained by individual characteristics. In this study, we highlight a 
6 considerable heterogeneity in both type and number of antihypertensive drug classes 
7 prescribed. Whether a specific drug combination or a more aggressive treatment is 
8 associated with better kidney and cardiovascular outcomes in real life remains to be 
9 evaluated. The widespread use prescription of RAAS inhibitors, which are consistently 
10 recommended in CKD, underscores the role of guidelines in the adoption of best practices. 
11 Further investigation of hypertension management in CKD is needed to bridge the gaps in 
12 current recommendations and improve patient outcomes.
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3 iNET-CKD membership prerequisites have been detailed elsewhere.26 iNET-CKD 
4 includes observational studies with defined objectives, patient-level information, and 
5 prospective data collection, and focuses on individuals with predialysis CKD. The present 
6 analysis consists of baseline data from 17 studies including participants aged ≥18 years, with 
7 eGFR <60 ml/min/1.73m² (neither dialyzed nor transplanted) and treated hypertension (under 
8 antihypertensive drug use). Information about study country, recruitment years, target 
9 population, and prevalence of treated hypertension is summarized in Supp Table S91.
10 Study variables
11 A variable dictionary was sent to each participating cohort study in order to harmonize 
12 data regarding covariate definitions, labeling, and coding (Appendix S1).  Glomerular filtration 
13 was estimated with either the CKD-EPI51 equation, except in CanPREDDICT and CKD-JAC 
14 studies, in whichor the MDRD52 equation and the 3-variable Japanese equation 53 were used, 
15 respectively. Albuminuria (or equivalent) was classified according to the Kidney Disease 
16 Improving Global Outcomes (KDIGO) 2012 guideline stages as A1 (normal to mildly 
17 increased), A2 (moderately increased), or A3 (severely increased).9 Body mass index (BMI) 
18 was calculated as weight (Kg) divided by square height (m). Diabetes was defined as serum 
19 fasting glucose ≥7.0 mmol/L (≥126 mg/dl), non-fasting glucose ≥11.1 mmol/l (≥200 mg/dl), 
20 glycated hemoglobin A1c ≥6.5%, or use of glucose-lowering drugs. If such information was 
21 not available, diabetes was identified by self-report or medical records. History of 
22 cardiovascular disease was defined as history of coronary artery disease, prior 
23 revascularization, heart failure, stroke or peripheral vascular disease. Education levels 
24 corresponded to the number of years of formal education reported by the participant at the 
25 baseline visit. Smoking status was dichotomized into current and not current smoking, except 
26 for one study in which participants were classified as ever or never smokers. 
27 Blood pressure control and antihypertensive treatment
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1 BP assessment method for each study is described in Supp Table S91. Most studies 
2 (10 of 17) provided an office BP value, while the other provided the mean of 3 BP readings 
3 obtained in compliance with a study protocol. We classified participants’ BP control status 
4 according to three thresholds for systolic and diastolic BP: 130/80 mm Hg, 140/90 mm Hg, 
5 and 150/90 mm Hg, the latter only in participants aged ≥60 years only. Antihypertensive 
6 drugs in useprescribed were identified by self-report or medical reports and classified into the 
7 following classes: renin-angiotensin-aldosterone system (RAAS) inhibitors, diuretics, 
8 calcium-channel blockers, beta-blockers, and other.
9 Statistical analyses
10 To address the study aims, we asked each study cohort to provide descriptive 
11 statistics regarding participants’ characteristics and antihypertensive drug useprescriptions. 
12 For each study, we also asked for three datasets containing grouped information including 
13 the number of participants having a particular profile, and respective number of participants 
14 with uncontrolled BP (one dataset for each BP threshold). This was equivalent to having 
15 individual data for each categorized covariate. Characteristics considered for participant 
16 profiling were age (<65 or ≥ 65 years), gender, diabetes, eGFR (≥ 30 or <30 ml/min/1.73m²), 
17 history of cardiovascular disease, BMI (<30 or ≥30 kg/m²), albuminuria (A1, A2 or A3), 
18 education attainment (<12 or ≥12 years of formal education), and smoking status (current or 
19 not). If 20% or more data was missing for a given variable, this variable was excluded from 
20 the dataset. Any participant with missing information for the remaining variables was 
21 excluded. 
22 Using these data, we described participants’ characteristics and BP control by study, 
23 world region (Asia, Australia, Europe, North America, and South America), and recruitment 
24 setting (nephrology or general practices). Categorical variables were presented as 
25 percentages and continuous variables as means ± standard deviations or medians 
26 (interquartile range). Using mixed logistic regression models with study-specific random 
27 intercepts and participant characteristics as fixed effects, we estimated prevalence ratios of 
28 uncontrolled BP (≥130/80, 140/90, or 150/90 mm Hg) for each cohort study. Prevalence 
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1 ratios correspond to the ratio of the true prevalence of uncontrolled BP for a given study 
2 cohort according to the model (predicted mean), divided by the prevalence that would be 
3 expected for a hypothetical cohort with the same case-mix and an intercept parameter equal 
4 to the population average (marginal mean) 54. The respective 95% confidence intervals were 
5 estimated with bias-corrected bootstrap methods. All adjustment variables were not available 
6 for some of the participating studies, either because they were not collected or because they 
7 were missing for ≥ 20% of participants (Table S10). Thus, we performed three adjustment 
8 models: the first included age, gender, diabetes, and eGFR (4-covariate model); the second 
9 further included albuminuria level, cardiovascular disease, and obesity status (7-covariate 
10 model), and the third one added smoking status and educational level (9-covariate model). 
11 These adjustment models (4, 7, or 9 covariates) which included a different set of studies 
12 depending on variable availability (17, 14, or 10 studies, respectively). We also ran crude 
13 models corresponding to each of these sets of studies. To test the era effect and the impact 
14 of the type of BP measurement in prevalence ratio estimates, we performed meta-
15 regressions of the prevalence ratio of uncontrolled BP ≥140/90 mm Hg obtained with the 4-
16 covariate model on the first year of recruitment, as a surrogate for year at BP measurement, 
17 and on the type of BP measurement. Antihypertensive drugs were described in terms of 
18 number and type of drug classes in use. Two-sided significance tests were used and P-
19 values <0.05 were considered significant. All sStatistical analyses were performed with SAS 
20 9.4 (SAS Institute Inc, Cary, NC) and R version 3.5.0.
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3 contributing in this iNET-CKD analysis are presented in Supplementary Table 1 Appendix S2 
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Page 48 of 91






























































For Peer Review Only
20
Supplementary material
Supplementary Table S1. Crude and adjusted prevalence ratios of uncontrolled blood 
pressure ≥130/80 mm Hg, by study.
Supplementary Table S2. Crude and adjusted prevalence ratios of uncontrolled blood 
pressure ≥140/90 mm Hg, by study.
Supplementary Table S3. Crude and adjusted prevalence ratios of uncontrolled blood 
pressure ≥150/90 mm Hg in patients aged 60 years or older, by study.
Supplementary Table S4. Adjusted odds ratios of uncontrolled blood pressure ≥130/80 mm 
Hg associated with patient characteristics.
Supplementary Table S5. Adjusted odds ratios of uncontrolled blood pressure ≥140/90 mm 
Hg associated with patient characteristics.
Supplementary Table S6. Adjusted odds ratios of uncontrolled blood pressure ≥150/90 mm 
Hg in patients aged 60 years or older associated with patient characteristics.
Supplementary Table S7. Number and type of antihypertensive drug classes prescribed by 
study.
Supplementary Tables S8.1 to S8.17. Patterns of antihypertensive drug prescription.
Supplementary Table S9. Study description and references.
Supplementary Appendix S1. Variable dictionary.
Supplementary Table S10. Missing covariates, by study.
Supplementary Appendix S2. Acknowledgement and funding for collaborating cohorts. 
Supplementary information is available at Kidney International's website.
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Table 1. Patient characteristics by study.


















CKD-JAC 1898 63 (55-70) 34.9 41.8 44.9 29.6 23.2 (21.1-25.8) 16.9 27.2 (18.3-37.4) 9.3 28.2 62.5
CORE-CKD 739 65 (58-70) 34.0 54.3 52.8 21.7 25.7 (23.2-29.1) 6.6 36.6 (28.1-47.4) 30.7 25.4 43.8
CSTRIDE 1305 52 (42-62) 39.2 27.1 29.7 14.1 24.5 (22.0-26.8) 39.9* 32.3 (22.4-43.2) 22.1 23.3 54.6
ICKD 676 50 (41-58) 31.2 45.4 30.9 12.9 24.1 (21.6-27.3) 16.0 39.5 (33.5-47.6) 56.8 17.3 25.9
KNOW-CKD 1313 58 (50-65) 36.3 36.9 34.7 17.4 24.1 (21.6-26.3) 15.3 33.1 (22.6-45.0) 30.4 23.2 46.5
Australia
CKD-QLD 1504 72 (63-79) 47.9 NA 54.3 56.3 30.2 (26.0-35.4) 8.4 34.0 (24.0-42.0) 27.6 31.4 41.0
Europe
CKD-REIN 2147 69 (61-77) 33.5 35.1 44.2 43.1 28.0 (24.9-32.0) 11.9 31.2 (22.9-40.2) 26.8 31.2 42
CKDopps DE 877 75 (67-80) 42.6 NA 43.3 30.7 29.0 (25.5-32.7) NA 26.0 (21.7-32.8) NA NA NA
GCKD 3734 65 (57-70) 36.9 46.8 39.2 34.6 29.3 (26.0-33.5) 14.4 42.0 (34.0-49.0) 43.1 30.8 26.1
PSI BIND-NL 517 63 (52-71) 33.1 78.9 20.1 38.1 27.0 (24.3-30.9) 16.8 30.9 (21.5-43.3) 27.5 21.1 51.5
North America
CanPREDDICT 2411 71 (62-77) 37.4 NA 49.5 57.3 28.7 (25.1-33.2) NA 27.0 (20.1-34.7) 25.5 35.6 38.9
CKDopps US 771 71 (61-78) 45.7 NA 60.7 45.7 31.3 (26.7-37.5) 9.7 25.0 (18.0-33.0) NA NA NA
CRIC 2801 61 (54-67) 44.9 43.976.5 53.5 38.0 31.3 (27.3-36.5) 13.0 39.8 (31.0-47.9) 35.2 27.5 37.3
South America
CKDopps BR 509 68 (59-77) 49.7 8.8 47.3 44.8 NA 7.3 24.0 (17.0-31.0) 42.8 17.5 24.2
NRHP prevalent 6460 73 (65-79) 41.9 NA 38.9 36.5 28.5 (25.3-32.1) 5.6 35.8 (26.9-44.8) 75.8 10.1 14.0
GP cohorts
NRHP incident 5257 72 (65-79) 43.6 NA 38.4 37.3 28.8 (25.6-32.5) 7.1 38.3 (29.8-46.5) 79.9 9.4 10.7
PROVALID 641 69 (64-79) 57.3 NA 100** 45.6 30.8 (25.2-34.5) 7.8 48.0 (39.4-51.1) 62.7 27.5 9.8
RRID 1042 76 (70-81) 53.4 23.1 22.2 27.0 28.7 (25.9-32.0) 4.1 48.1 (41.6-54.1) 77.4 19.2 3.4
Abbreviations: IQR, interquartile range; CVD, cardiovascular disease; BMI, body mass index; eGFR, estimated glomerular filtration rate; GP: general practice; NA, not available or missing at ≥20%.
*Current or former smoking. **PROVALID included only patients with diabetes.
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Table 2. Mean systolic and diastolic blood pressure (mm Hg), and prevalence of uncontrolled 



















CKD-JAC 132.2 (18.0) 76.6 (11.7) 60.6 32.6 19.9 Study protocol
CORE-CKD 138.9 (18.6) 77.7 (12.0) 73.1 45.5 27.4 Study protocol
CSTRIDE 133.8 (17.6) 82.8 (11.1) 75.8 40.1 24.9 Study protocol
ICKD 135.2 (19.8) 83.2 (10.8) 80.2 47.3 32.7 Study protocol
KNOW-CKD 129.2 (16.8) 76.6 (11.1) 60.5 27.3 17.8 Office BP
Australia
CKD-QLD 133.6 (20.2) 71.4 (11.6) 64.0 38.5 24.1 Office BP
Europe
CKD-REIN 143.9 (20.2) 78.5 (12.2) 83.8 60.9 42.6 Office BP
CKDopps DE 138.5 (16.7) 76.2 (9.9) 79.7 49.5 23.6 Office BP
GCKD 140.6 (20.6) 78.7 (12.0) 75.2 51.0 38.0 Study protocol
PSI BIND-NL 138.9 (19.8) 82.5 (11.7) 77.2 50.1 41.5 Office BP
North America
CanPREDDICT 134.3 (20.0) 70.8 (11.9) 63.6 37.5 23.6 Office BP
CKDopps US 136.6 (20.8) 72.7 (11.8) 66.4 43.5 23.7 Office BP
CRIC 131.0 (22.3) 71.2 (12.9) 54.3 33.9 20.9 Study protocol
South America
CKDopps BR 134.1 (21.0) 79.3 (12.0) 79.2 49.5 32.3 Office BP
NRHP prevalent 133.1 (20.6) 75.7 (12.3) 70.6 43.6 27.9 Office BP
GP cohorts
NRHP incident 134.7 (22.4) 76.0 (12.9) 70.9 46.7 30.2 Office BP
PROVALID 136.4 (20.4) 77.8 (11.8) 81.0 46.6 7.9 Office BP
RRID 134.7 (19.1) 70.9 (11.1) 61.7 37.6 20.2 Study protocol
*Among patients aged 60 years or over.
**See more details about BP measurement methods in Supp Table 1.
Abbreviations: GP, general practice; SBP, systolic blood pressure; DBP, diastolic blood pressure.
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Table 3. Patterns of antihypertensive drug prescription. In the left table, frequency of each antihypertensive drug class is reported according to 
the number of prescribed classes. The right table reports the frequency of two-by-two associations between antihypertensive drug classes. 
































65.266.3% 70.371.1% 83.784.2% 94.393.4% 21.923.0%, 
alone 74.1% 68.7% 69.9% 64.9%
Diuretics 9.79.4% 52.753.7% 76.579.1% 90.691.7% 52.3% 4.6%, alone 56.1% 63.9% 69.1%
CCB 14.614.2% 34.935.1% 56.157.2% 83.189.3% 38.8% 44.9% 8.7%, alone 47.0% 63.0%
β-blockers 9.69.3% 32.132.6% 60.763.2% 82.085.0% 38.3% 49.6% 45.6% 5.9%, alone 54.5%
Other 0.9% 5.04.9% 10.410.3% 35.140.1% 8.9% 13.4% 15.2% 13.6% 2.2%, alone
Abbreviations: RAAS inhibitors, renin-angiotensin-aldosterone system inhibitors; CCB, calcium channel blockers.
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Figures
Figure 1A-C. Adjusted prevalence ratios of blood pressure ≥130/80 or ≥140/90 mm Hg by 
study. 
Values above 1 indicate lower frequency of blood pressure control than expected, given 
study patient characteristics. A: Adjusted for age, gender, diabetes status, and eGFR 
category; B: Further adjusted for history of cardiovascular disease, obesity, and albuminuria 
category; C: Further adjusted for education and smoking status. Abbreviations: AU, Australia; 
PR, prevalence ratio; CI, confidence interval; GP, general practice; NA, not available.
Figure 2. Adjusted prevalence ratios of uncontrolled blood pressure ≥140/90 mm Hg 
according to the year at study start, by study. 
Prevalence ratio values above 1 indicate lower frequency of blood pressure control than 
expected, given study patient characteristics. R², β, and p values were estimated with meta-
regression analysis of prevalence ratios of uncontrolled blood pressure ≥140/90 mm Hg 
adjusted for age, gender, diabetes status, and eGFR category on the year at study start, as 
surrogate of year at BP measurement. Abbreviations: PR, prevalence ratio; BP, blood 
pressure; GP, general practice.
Figure 3. Number of antihypertensive drug classes prescribed by study.
Abbreviations: AU, Australia; GP, general practice.
Figure 4. Type of antihypertensive drug classes prescribed by study.
Abbreviations: RAAS, Renin-angiotensin-aldosterone system; GP, general practice.
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Figure 2. Adjusted prevalence ratios of uncontrolled blood pressure ≥140/90 mm Hg according to the year 
at study start, by study. 
Prevalence ratio values above 1 indicate lower frequency of blood pressure control than expected, given 
study patient characteristics. R², β, and p values were estimated with meta-regression analysis of 
prevalence ratios of uncontrolled blood pressure ≥140/90 mm Hg adjusted for age, gender, diabetes status, 
and eGFR category on the year at study start, as surrogate of year at BP measurement. Abbreviations: PR, 
prevalence ratio; BP, blood pressure; GP, general practice. 
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Figure 3. Number of antihypertensive drug classes prescribed by study. 
Abbreviations: AU, Australia; GP, general practice. 
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Figure 4. Type of antihypertensive drug classes prescribed by study. 
Abbreviations: RAAS, Renin-angiotensin-aldosterone system; GP, general practice. 
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Supplementary Table S1. Crude and adjusted prevalence ratios of uncontrolled blood pressure ≥130/80 mm Hg, by study. Values above 1 
indicate lower frequency of blood pressure control than expected, given study patient characteristics. A: Adjusted for age, gender, diabetes 
status, and GFR category; B: Further adjusted for history of cardiovascular disease, obesity, and albuminuria category; C: Further adjusted for 
education and smoking status.













CanPREDDICT 0.89 (0.86-0.92) 0.88 (0.86-0.91) 0.90 (0.87-0.93) 0.89 (0.86-0.91) NA NA
CKD-JAC 0.85 (0.82-0.88) 0.84 (0.81-0.87) 0.86 (0.83-0.89) 0.82 (0.80-0.85) 0.86 (0.82-0.89) 0.83 (0.80-0.85)
CKD-QLD 0.90 (0.86-0.93) 0.90 (0.87-0.93) 0.91 (0.87-0.94) 0.89 (0.86-0.92) NA NA
CKD-REIN 1.15 (1.13-1.18) 1.15 (1.12-1.17) 1.17 (1.14-1.19) 1.13 (1.11-1.15) 1.16 (1.14-1.18) 1.13 (1.11-1.15)
CKDopps-BR 1.10 (1.05-1.14) 1.09 (1.04-1.13) NA NA NA NA
CKDopps-DE 1.11 (1.07-1.14) 1.10 (1.07-1.14) NA NA NA NA
CKDopps-US 0.93 (0.89-0.98) 0.92 (0.88-0.97) NA NA NA NA
CORE-CKD 1.02 (0.98-1.06) 1.02 (0.98-1.06) 1.03 (0.99-1.08) 1.01 (0.97-1.05) 1.03 (0.99-1.07) 1.02 (0.98-1.06)
CRIC 0.76 (0.73-0.79) 0.76 (0.73-0.79) 0.77 (0.74-0.80) 0.76 (0.73-0.79) 0.77 (0.74-0.80) 0.73 (0.70-0.76)
CSTRIDE 1.06 (1.03-1.09) 1.06 (1.02-1.09) 1.07 (1.04-1.10) 1.03 (1.00-1.06) 1.07 (1.04-1.10) 1.05 (1.01-1.08)
GCKD 1.05 (1.03-1.07) 1.06 (1.04-1.09) 1.06 (1.04-1.08) 1.08 (1.06-1.10) 1.06 (1.04-1.08) 1.10 (1.07-1.12)
ICKD 1.12 (1.08-1.15) 1.12 (1.08-1.16) 1.13 (1.09-1.16) 1.18 (1.14-1.23) 1.13 (1.09-1.16) 1.20 (1.16-1.25)
KNOW-CKD 0.85 (0.81-0.88) 0.85 (0.81-0.88) 0.86 (0.82-0.89) 0.85 (0.81-0.88) 0.86 (0.82-0.89) 0.86 (0.82-0.89)
NRHP incident* 0.99 (0.97-1.01) 1.00 (0.99-1.03) 1.00 (0.98-1.02) 1.07 (1.05-1.09) NA NA
NRHP 
prevalent
0.99 (0.97-1.01) 1.00 (0.98-1.02) 1.00 (0.98-1.02) 1.06 (1.04-1.09) NA NA
PROVALID* 1.13 (1.09-1.16) 1.12 (1.07-1.16) 1.14 (1.10-1.18) 1.19 (1.14-1.23) NA NA
PSI BIND-NL 1.07 (1.03-1.12) 1.08 (1.03-1.12) 1.09 (1.04-1.13) 1.06 (1.02-1.10) 1.09 (1.04-1.13) 1.08 (1.04-1.12)
RRID* 0.87 (0.83-0.91) 0.89 (0.85-0.94) 0.88 (0.84-0.92) 0.93 (0.88-0.97) 0.87 (0.83-0.91) 0.94 (0.89-0.99)
Abbreviations: PR, prevalence ratio; CI, confidence interval; NA, not available.
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Supplementary Table S2. Crude and adjusted prevalence ratios of uncontrolled blood pressure ≥140/90 mm Hg, by study. Values above 1 
indicate lower frequency of blood pressure control than expected, given study patient characteristics. A: Adjusted for age, gender, diabetes 
status, and GFR category; B: Further adjusted for history of cardiovascular disease, obesity, and albuminuria category; C: Further adjusted for 
education and smoking status.













CanPREDDICT 0.87 (0.83-0.91) 0.85 (0.81-0.89) 0.89 (0.84-0.93) 0.84 (0.80-0.88) NA NA
CKD-JAC 0.76 (0.72-0.81) 0.75 (0.71-0.80) 0.77 (0.72-0.82) 0.71 (0.67-0.75) 0.78 (0.73-0.82) 0.70 (0.66-0.74)
CKD-QLD 0.90 (0.85-0.96) 0.88 (0.83-0.94) 0.91 (0.86-0.97) 0.86 (0.81-0.91) NA NA
CKD-REIN 1.36 (1.31-1.41) 1.33 (1.29-1.38) 1.39 (1.34-1.44) 1.29 (1.24-1.33) 1.40 (1.35-1.45) 1.26 (1.21-1.30)
CKDopps-BR 1.14 (1.05-1.22) 1.11 (1.03-1.20) NA NA NA NA
CKDopps-DE 1.14 (1.07-1.21) 1.11 (1.04-1.18) NA NA NA NA
CKDopps-US 1.01 (0.93-1.08) 0.96 (0.89-1.03) NA NA NA NA
CORE-CKD 1.05 (0.98-1.13) 1.05 (0.97-1.13) 1.07 (1.00-1.15) 1.02 (0.95-1.10) 1.08 (1.00-1.16) 1.03 (0.96-1.12)
CRIC 0.79 (0.75-0.83) 0.80 (0.76-0.84) 0.80 (0.76-0.84) 0.79 (0.75-0.82) 0.81 (0.76-0.85) 0.74 (0.70-0.79)
CSTRIDE 0.93 (0.87-0.99) 0.96 (0.90-1.02) 0.95 (0.89-1.01) 0.93 (0.87-0.98) 0.95 (0.89-1.01) 0.95 (0.88-1.01)
GCKD 1.18 (1.14-1.22) 1.22 (1.18-1.26) 1.21 (1.17-1.24) 1.24 (1.20-1.28) 1.21 (1.17-1.25) 1.29 (1.24-1.34)
ICKD 1.09 (1.02-1.17) 1.16 (1.07-1.24) 1.11 (1.04-1.20) 1.26 (1.18-1.37) 1.12 (1.04-1.20) 1.33 (1.24-1.45)
KNOW-CKD 0.64 (0.59-0.70) 0.65 (0.60-0.71) 0.66 (0.60-0.71) 0.65 (0.60-0.71) 0.65 (0.60-0.71) 0.65 (0.60-0.71)
NRHP incident* 1.08 (1.05-1.12) 1.10 (1.06-1.14) 1.10 (1.07-1.14) 1.23 (1.18-1.28) NA NA
NRHP 
prevalent
1.01 (0.98-1.04) 1.02 (0.99-1.05) 1.03 (1.00-1.06) 1.13 (1.10-1.18) NA NA
PROVALID* 1.08 (0.99-1.15) 1.03 (0.94-1.10) 1.10 (1.01-1.18) 1.13 (1.03-1.22) NA NA
PSI BIND-NL 1.15 (1.06-1.25) 1.18 (1.09-1.29) 1.17 (1.08-1.28) 1.13 (1.04-1.22) 1.18 (1.09-1.28) 1.20 (1.11-1.29)
RRID* 0.88 (0.81-0.94) 0.92 (0.85-0.99) 0.89 (0.82-0.96) 1.00 (0.92-1.07) 0.90 (0.83-0.96) 1.03 (0.94-1.11)
Abbreviations: PR, prevalence ratio; CI, confidence interval; NA, not available.
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Supplementary Table S3. Crude and adjusted prevalence ratios of uncontrolled blood pressure ≥150/90 mm Hg in patients aged 60 years or 
older, by study. Values above 1 indicate lower frequency of blood pressure control than expected, given study patient characteristics. A: 
Adjusted for age, gender, diabetes status, and GFR category; B: Further adjusted for history of cardiovascular disease, obesity, and albuminuria 
category; C: Further adjusted for education and smoking status.













CanPREDDICT 0.92 (0.85-0.99) 0.91 (0.84-0.98) 0.92 (0.85-1.00) 0.91 (0.84-0.99) NA NA
CKD-JAC 0.78 (0.70-0.87) 0.77 (0.69-0.85) 0.78 (0.69-0.87) 0.69 (0.61-0.77) 0.72 (0.64-0.81) 0.63 (0.56-0.70)
CKD-QLD 0.94 (0.85-1.03) 0.94 (0.85-1.03) 0.95 (0.85-1.03) 0.90 (0.81-0.99) NA NA
CKD-REIN 1.65 (1.55-1.75) 1.65 (1.55-1.75) 1.66 (1.57-1.77) 1.56 (1.47-1.66) 1.53 (1.44-1.63) 1.44 (1.35-1.54)
CKDopps-BR 1.24 (1.08-1.42) 1.22 (1.05-1.39) NA NA NA NA
CKDopps-DE 0.92 (0.81-1.04) 0.91 (0.80-1.03) NA NA NA NA
CKDopps-US 0.92 (0.81-1.05) 0.90 (0.79-1.02) NA NA NA NA
CORE-CKD 1.06 (0.91-1.20) 1.05 (0.90-1.19) 1.07 (0.92-1.19) 1.00 (0.85-1.12) 0.99 (0.85-1.09) 0.97 (0.82-1.09)
CRIC 0.82 (0.74-0.89) 0.81 (0.74-0.89) 0.82 (0.75-0.90) 0.80 (0.72-0.88) 0.76 (0.69-0.83) 0.69 (0.62-0.78)
CSTRIDE 0.97 (0.82-1.12) 0.96 (0.81-1.10) 0.98 (0.82-1.13) 0.89 (0.76-1.02) 0.90 (0.76-1.04) 0.86 (0.73-1.00)
GCKD 1.48 (1.40-1.56) 1.51 (1.42-1.60) 1.49 (1.40-1.57) 1.55 (1.46-1.64) 1.37 (1.29-1.45) 1.54 (1.43-1.64)
ICKD 1.24 (1.02-1.51) 1.25 (1.00-1.50) 1.25 (1.02-1.52) 1.26 (1.00-1.53) 1.15 (0.95-1.37) 1.27 (1.02-1.53)
KNOW-CKD 0.71 (0.59-0.83) 0.70 (0.59-0.83) 0.71 (0.59-0.84) 0.67 (0.56-0.78) 0.66 (0.55-0.77) 0.63 (0.53-0.74)
NRHP incident* 1.17 (1.11-1.23) 1.21 (1.14-1.27) 1.18 (1.11-1.24) 1.39 (1.31-1.47) NA NA
NRHP 
prevalent
1.09 (1.03-1.14) 1.11 (1.05-1.17) 1.09 (1.04-1.15) 1.28 (1.21-1.36) NA NA
PROVALID* 0.35 (0.26-0.44) 0.34 (0.25-0.42) 0.34 (0.26-0.43) 0.37 (0.27-0.46) NA NA
PSI BIND-NL 1.58 (1.39-1.78) 1.61 (1.42-1.82) 1.59 (1.39-1.78) 1.48 (1.27-1.65) 1.46 (1.28-1.64) 1.45 (1.26-1.62)
RRID* 0.79 (0.70-0.89) 0.84 (0.74-0.94) 0.80 (0.70-0.89) 0.93 (0.82-1.04) 0.74 (0.65-0.82 0.92 (0.81-1.04)
Abbreviations: PR, prevalence ratio; CI, confidence interval; NA, not available.
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Supplementary Table S4. Adjusted odds ratios of uncontrolled blood pressure ≥130/80 mm Hg associated with patient characteristics. A: 
Adjusted for age, gender, diabetes status, and GFR category; B: Further adjusted for history of cardiovascular disease, obesity, and albuminuria 
category; C: Further adjusted for education and smoking status.
Variable A B C
OR (95%CI) p OR (95%CI) p OR (95%CI) p
Age (≥65 years) 0.94 (0.89- 0.99) 0.023 1.10 (1.04- 1.17) 0.001 1.12 (1.03- 1.21) 0.005
Gender (women) 0.88 (0.84- 0.93) <0.001 0.90 (0.85- 0.94) <0.001 0.85 (0.79- 0.91) <0.001
Diabetes 1.19 (1.14- 1.25) <0.001 1.11 (1.06- 1.17) <0.001 1.12 (1.04- 1.21) 0.002
GFR category (G4 or G5) 1.13 (1.08- 1.20) <0.001 1.01 (0.95- 1.07) 0.778 0.96 (0.88- 1.04) 0.230
History of CVD 0.81 (0.77- 0.86) <0.001 0.92 (0.85- 0.99) 0.032
BMI (≥30 kg/m²) 1.15 (1.08- 1.21) <0.001 1.04 (0.96- 1.13) 0.349
Albuminuria category <0.001 <0.001
A1 1 1
A2 1.32 (1.24- 1.41) 1.42 (1.30- 1.55)
A3 2.16 (2.02- 2.32) 2.38 (2.17- 2.61)
Education (≥12 years) 0.84 (0.78- 0.91) <0.001
Current smoking 0.95 (0.86- 1.05) 0.343
Abbreviations: OR, odds ratio; CI, confidence interval; GFR, glomerular filtration rate; CVD, cardiovascular disease; BMI, body mass index.
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Supplementary Table S5. Adjusted odds ratios of uncontrolled blood pressure ≥140/90 mm Hg associated with patient characteristics. A: 
Adjusted for age, gender, diabetes status, and GFR category; B: Further adjusted for history of cardiovascular disease, obesity, and albuminuria 
category; C: Further adjusted for education and smoking status.
Variable A B C
OR (95%CI) p OR (95%CI) p OR (95%CI) p
Age (≥65 years) 1.07 (1.02- 1.12) 0.007 1.26 (1.20- 1.33) <0.001 1.34 (1.25- 1.45) <0.001
Gender (women) 0.93 (0.89- 0.97) 0.002 0.94 (0.89- 0.98) 0.005 0.87 (0.81- 0.93) <0.001
Diabetes 1.28 (1.22- 1.34) <0.001 1.18 (1.12- 1.23) <0.001 1.27 (1.19- 1.37) <0.001
GFR category (G4 or G5) 1.16 (1.11- 1.22) <0.001 1.03 (0.98- 1.09) 0.242 1.05 (0.97- 1.13) 0.268
History of CVD 0.87 (0.82- 0.91) <0.001 0.96 (0.89- 1.03) 0.231
BMI (≥30 kg/m²) 1.16 (1.10- 1.22) <0.001 1.01 (0.94- 1.10) 0.707
Albuminuria category <0.001 <0.001
A1 1 1
A2 1.26 (1.19- 1.35) 1.37 (1.26- 1.49)
A3 2.11 (1.98- 2.25) 2.40 (2.20- 2.61)
Education (≥12 years) 0.81 (0.76- 0.87) <0.001
Current smoking 0.91 (0.83- 1.00) 0.041
Abbreviations: OR, odds ratio; CI, confidence interval; GFR, glomerular filtration rate; CVD, cardiovascular disease; BMI, body mass index.
Page 67 of 91






























































For Peer Review Only
Supplementary Table S6. Adjusted odds ratios of uncontrolled blood pressure ≥150/90 mm Hg in patients aged 60 years or older associated 
with patient characteristics. A: Adjusted for age, gender, diabetes status, and GFR category; B: Further adjusted for history of cardiovascular 
disease, obesity, and albuminuria category; C: Further adjusted for education and smoking status.
Variable A B C
OR (95%CI) p OR (95%CI) p OR (95%CI) p
Age (≥65 years) 0.91 (0.84- 0.98) 0.012 1.00 (0.93- 1.09) 0.935 1.06 (0.96- 1.19) 0.256
Gender (women) 1.00 (0.94- 1.06) 0.972 1.02 (0.96- 1.09) 0.453 1.00 (0.90- 1.10) 0.946
Diabetes 1.15 (1.09- 1.22) <0.001 1.04 (0.97- 1.10) 0.2514 1.01 (0.92- 1.11) 0.798
GFR category (G4 or G5) 1.08 (1.01- 1.15) 0.016 0.94 (0.88- 1.00) 0.065 0.93 (0.84- 1.04) 0.210
History of CVD 0.85 (0.80- 0.91) <0.001 0.96 (0.88- 1.06) 0.430
BMI (≥30 kg/m²) 1.12 (1.05- 1.19) 0.001 0.98 (0.88- 1.08) 0.666
Albuminuria category <0.001 <0.001
A1 1 1
A2 1.26 (1.17- 1.37) 1.39 (1.24- 1.57)
A3 2.24 (2.07- 2.43) 2.73 (2.42- 3.08)
Education (≥12 years) 0.81 (0.73- 0.89) <0.001
Current smoking 0.90 (0.78- 1.05) 0.177
Abbreviations: OR, odds ratio; CI, confidence interval; GFR, glomerular filtration rate; CVD, cardiovascular disease; BMI, body mass index.
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Supplementary Table S7. Number and type of antihypertensive drug classes prescribed by study.
Number of antihypertensive drug 
classes (%) Type of antihypertensive drug classes
Study N








CanPREDDICT 2411 13.7 23.8 31.5 30.9 74.2 4.9 75.6 58.1 47.9 24.5
CKD-JAC 1898 26.1 27.8 20.9 25.2 37.2 6.0 89.1 61.7 22.2 15.3
CKD-QLD 1504 23.8 30.2 27.9 18.2 47.5 3.3 73.0 50.1 49.7 19.5
CKD-REIN 2147 20.0 30.2 29.9 19.9 58.2 4.5 81.6 54.3 45.6 13.4
CKDopps BR 509 13.8 30.6 33.6 22.0 79.4 9.2 67.8 40.3 47.9 29.9
CKDopps DE 877 8.7 23.7 37.1 30.6 77.9 8.6 80.5 52.5 70.2 11.7
CKDopps US 771 15.6 22.7 31.0 30.7 65.9 5.2 54.3 54.7 62.9 40.5
CORE-CKD 739 30.9 37.5 18.8 12.9 26.4 1.1 57.0 61.3 41.1 25.6
CRIC 2801 16.9 29.7 32.6 20.8 68.3 4.3 76.3 48.3 56.7 10.6
CSTRIDE 1305 36.4 36.0 18.5 9.1 11.2 NA 63.1 75.0 37.5 10.1
GCKD 3734 14.0 33.4 34.6 17.9 67.4 NA 76.9 41.2 61.7 4.5
ICKD 676 NA NA NA NA NA <1.0 NA NA NA NA
KNOW-CKD 1313 26.4 32.4 24.3 16.8 41.8 3.0 90.5 53.1 32.3 11.5
NRHP incident 5257 38.8 39.9 17.8 3.5 49.4 NA 76.9 26.7 29.7 1.8
NRHP prevalent 6460 38.5 39.4 18.1 3.9 48.7 NA 74.3 28.7 30.0 2.6
PROVALID 641 12.2 23.4 31.5 32.9 71.3 NA 87.4 41.2 66.5 26.2
PSI BIND-NL 517 29.0 29.2 25.3 16.4 54.9 7.2 79.9 30.2 46.8 4.8
RRID 1042 30.7 40.3 21.0 8.0 51.8 2.5 80.8 35.4 27.1 11.8
* Included in diuretic statistics.
Abbreviations: RAAS, Renin-angiotensin-aldosterone system; NA, not available; MRA, mineralocorticoid receptor antagonists
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Supplementary Tables S8.1 to S8.17. Patterns of antihypertensive drug prescription. In the left table, frequency of each antihypertensive drug 
class according to the number of classes prescribed. In the right table, frequency of two-by-two association between antihypertensive drug 
classes. Abbreviations: RAAS, renin-angiotensin-aldosterone system; CCB, calcium channel blockers. 
8.1- CanPREDDICT






















inhibitors 54.1% 65.2% 78.4% 90.3% 9.8%,alone 74.3% 73.4% 73.0% 68.1%
Diuretics 23.0% 56.9% 86.8% 97.3% 72.8% 4.3%, alone 78.7% 79.8% 89.3%
CCB 12.7% 39.8% 62.3% 87.9% 56.4% 61.6% 3.0%, alone 59.7% 70.0%
β-blockers 9.1% 28.2% 49.0% 79.2% 46.2% 51.6% 49.3% 2.6%, alone 56.6%
Other 1.2% 6.6% 18.7% 54.4% 22.1% 29.5% 29.5% 28.9% 0.7%, alone
8.2- CKD-JAC






















inhibitors 79.6% 88.8% 94.4% 94.8% 23.4%, alone 85.6% 87.5% 84.3% 87.2%
Diuretics 6.0% 18.0% 41.4% 69.2% 31.4% 4.8%, alone 36.1% 48.5% 45.9%
CCB 11.9% 64.0% 85.1% 91.4% 60.6% 68.2% 5.0%, alone 79.1% 88.6%
β-blockers 1.6% 9.1% 24.5% 56.1% 21.0% 32.9% 28.4% 1.9%, alone 44.8%
Other 0.8% 3.4% 13.9% 44.6% 15.0% 21.5% 21.9% 30.9% 1.4%, alone
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8.3- CKD-QLD






















inhibitors 58.4% 63.7% 82.3% 93.4% 19.0%, alone 73.2% 68.8% 66.0% 68.3%
Diuretics 7.8% 35.5% 69.9% 85.0% 47.6% 3.9%, alone 48.5% 55.2% 54.3%
CCB 16.2% 45.8% 59.2% 87.9% 47.3% 51.3% 7.7%, alone 48.3% 71.0%
β-blockers 15.9% 44.3% 63.5% 82.1% 45.0% 57.8% 47.9% 7.6%, alone 58.4%
Other 1.7% 8.8% 19.8% 60.1% 18.2% 22.3% 27.6% 22.9% 2.0%, alone
8.4- CKD-REIN






















inhibitors 67.2% 77.2% 86.6% 95.1% 16.5%, alone 80.5% 79.4% 76.5% 77.4%
Diuretics 9.5% 46.6% 78.9% 93.7% 57.5% 3.3%, alone 61.9% 66.7% 72.6%
CCB 14.0% 40.4% 67.9% 95.6% 52.9% 57.8% 5.1%, alone 56.8% 79.2%
β-blockers 8.6% 32.3% 56.8% 86.4% 42.8% 52.3% 47.8% 3.8%, alone 55.6%
Other 0.7% 3.5% 9.8% 46.5% 12.7% 16.7% 19.6% 16.3% 1.0%, alone
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8.5- CKDopps BR






















inhibitors 51.4% 59.6% 72.5% 82.1% 11.4%, alone 65.8% 61.5% 63.1% 56.6%
Diuretics 31.4% 76.3% 88.9% 99.1% 77.1% 5.4%, alone 81.5% 82.4% 85.5%
CCB 11.0% 23.1% 49.1% 69.6% 36.5% 41.3% 3.4%, alone 38.9% 43.4%
β-blockers 4.3% 30.8% 57.3% 84.8% 44.6% 49.8% 46.3% 1.2%, alone 61.8%
Other 2.9% 9.6% 30.4% 74.1% 24.9% 32.2% 32.2% 38.5% 1.3%, alone
8.6- CKDopps DE






















inhibitors 51.3% 62.5% 85.2% 97.0% 5.5%, alone 80.4% 81.7% 78.4% 82.5%
Diuretics 15.8% 64.9% 85.2% 96.6% 77.8% 1.8%, alone 78.9% 80.8% 88.3%
CCB 11.5% 22.6% 47.1% 94.0% 53.3% 53.1% 1.7%, alone 53.2% 79.6%
β-blockers 19.7% 48.6% 77.5% 92.5% 68.4% 72.9% 71.3% 2.4%, alone 76.7%
Other 2.6% 0.5% 3.7% 32.8% 12.0% 13.3% 17.8% 12.8% 1.9%, alone
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8.7- CKDopps US






















inhibitors 31.7% 45.7% 54.4% 72.2% 9.1%, alone 55.3% 53.1% 50.5% 45.5%
Diuretics 16.7% 54.9% 74.5% 90.3% 67.1% 3.9%, alone 64.7% 69.9% 73.1%
CCB 21.7% 38.9% 56.5% 81.4% 53.5% 53.7% 6.2%, alone 55.5% 58.0%
β-blockers 24.2% 45.1% 67.4% 91.1% 58.5% 66.7% 63.7% 6.0%, alone 71.5%
Other 5.8% 15.4% 43.1% 73.8% 33.9% 44.9% 42.9% 46.0% 2.2%, alone
8.8- CORE-CKD






















inhibitors 50.9% 50.2% 69.8% 72.6% 27.6%, alone 52.8% 49.7% 47.4% 38.1%
Diuretics 3.1% 20.2% 45.3% 72.6% 24.5% 3.6%, alone 28.3% 30.9% 36.0%
CCB 28.5% 66.4% 84.9% 90.5% 53.4% 65.6% 14.3%, alone 64.8% 65.6%
β-blockers 12.7% 39.0% 62.6% 84.2% 34.2% 48.2% 43.5% 9.5%, alone 46.6%
Other 4.8% 22.0% 32.4% 75.8% 17.1% 34.9% 27.4% 28.9% 5.8%, alone
Page 73 of 91






























































For Peer Review Only
8.9- CRIC






















inhibitors 60.5% 65.2% 83.4% 93.8% 13.4%, alone 75.5% 72.1% 72.8% 71.7%
Diuretics 12.0% 59.4% 87.0% 97.3% 67.5% 3.0%, alone 72.6% 75.5% 80.5%
CCB 13.5% 31.3% 53.8% 92.0% 45.6% 51.4% 4.7%, alone 49.1% 66.0%
β-blockers 13.1% 41.2% 69.5% 94.2% 54.1% 62.7% 57.6% 3.9%, alone 69.0%
Other 0.8% 2.9% 6.3% 36.3% 10.0% 12.5% 14.5% 12.9% 1.3%, alone
8.10- CSTRIDE






















inhibitors 49.3% 60.9% 79.3% 95.0% 28.4%, alone 67.8% 53.9% 53.5% 56.8%
Diuretics 1.5% 5.5% 18.3% 58.0% 12.0% 4.8%, alone 12.3% 17.3% 23.5%
CCB 44.8% 89.1% 94.6% 100.0% 64.1% 82.2% 21.8%, alone 90.2% 90.9%
β-blockers 3.4% 37.7% 77.6% 92.4% 31.8% 58.2% 45.1% 3.3%, alone 68.2%
Other 1.1% 3.2% 21.2% 51.3% 9.1% 21.2% 12.3% 18.4% 3.8%, alone
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8.11- GCKD






















inhibitors 77.1% 57.1% 83.9% 100.0% 14.1%, alone 72.3% 74.5% 75.8% 0.0%
Diuretics 0.0% 60.1% 85.8% 98.5% 63.4% 0.0%, alone 74.1% 74.4% 95.8%
CCB 6.5% 23.2% 45.4% 93.6% 39.9% 45.2% 2.2%, alone 44.1% 0.0%
β-blockers 15.1% 44.1% 79.8% 96.1% 60.8% 68.1% 66.0% 3.4%, alone 0.0%
Other 1.3% 12.9% 0.0% 0.0% 0.0% 6.4% 0.0% 0.0% 4.2%, alone
8.12- KNOW-CKD






















inhibitors 83.9% 92.0% 91.5% 96.4% 24.5%, alone 89.6% 87.7% 84.0% 84.1%
Diuretics 4.6% 36.4% 58.6% 86.4% 41.4% 2.9%, alone 45.5% 50.0% 51.7%
CCB 8.1% 48.4% 79.6% 94.6% 51.4% 57.7% 4.0%, alone 73.3% 70.9%
β-blockers 3.2% 16.7% 47.0% 86.9% 30.0% 38.6% 44.6% 2.6%, alone 58.3%
Other 0.3% 4.5% 13.2% 40.3% 11.7% 14.2% 15.4% 20.8% 0.7%, alone
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8.13- NRHP incident






















inhibitors 70.4% 76.3% 88.4% 97.3% 35.5%, alone 72.1% 54.7% 65.0% 62.5%
Diuretics 9.7% 65.7% 89.6% 98.9% 46.3% 7.6%, alone 53.4% 56.2% 62.5%
CCB 11.4% 26.1% 49.4% 85.4% 18.9% 28.8% 16.6%, alone 24.5% 40.6%
β-blockers 8.4% 29.4% 65.0% 88.6% 25.1% 33.8% 27.3% 11.0%, alone 34.4%
Other 0.1% 1.2% 4.3% 15.1% 1.5% 2.3% 2.8% 2.1% 2.1%, alone
8.14- NRHP prevalent





















inhibitors 66.5% 74.0% 86.4% 96.4% 34.5%, alone 69.0% 51.9% 62.8% 52.1%
Diuretics 11.1% 62.5% 88.3% 97.2% 45.3% 8.8%, alone 51.2% 55.5% 60.0%
CCB 13.5% 28.4% 49.7% 85.4% 20.1% 30.2% 18.1%, alone 27.6% 35.8%
β-blockers 8.2% 30.2% 63.6% 87.4% 25.4% 34.2% 28.8% 11.5%, alone 35.8%
Other 0.7% 1.8% 4.8% 17.8% 1.8% 3.1% 3.2% 3.0% 11.3%, alone
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8.15- PROVALID






















inhibitors 52.6% 82.7% 93.1% 98.1% 7.3%, alone 92.8% 88.6% 83.8% 91.7%
Diuretics 0.0% 55.3% 83.2% 97.6% 75.7% 0.0%, alone 76.1% 75.4% 82.7%
CCB 9.0% 16.7% 37.6% 73.9% 41.8% 44.0% 2.7%, alone 42.3% 49.4%
β-blockers 37.2% 38.0% 72.8% 91.5% 63.8% 70.2% 68.2% 6.8%, alone 73.8%
Other 1.3% 7.3% 12.9% 61.6% 27.5% 30.4% 31.4% 29.1% 0.6%, alone
8.16- PSI BIND-NL






















inhibitors 69.3% 77.5% 86.3% 92.9% 25.2%, alone 77.1% 75.6% 72.7% 100.0%
Diuretics 14.7% 54.3% 74.0% 97.6% 53.0% 7.7%, alone 11.3% 58.3% 76.0%
CCB 6.0% 17.9% 45.0% 71.8% 28.6% 5.6% 5.8%, alone 38.0% 64.0%
β-blockers 12.7% 45.7% 65.6% 80.0% 42.6% 49.6% 59.0% 7.9%, alone 64.0%
Other 0.0% 2.0% 6.1% 16.5% 6.1% 6.7% 11.3% 6.6% 0.0%, alone
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8.17- RRID






















inhibitors 68.8% 81.0% 91.3% 98.8% 26.1%, alone 80.7% 75.1% 65.6% 77.2%
Diuretics 10.6% 60.0% 79.0% 97.6% 51.8% 6.3%, alone 54.7% 46.8% 63.4%
CCB 9.1% 28.8% 66.2% 89.2% 32.9% 37.4% 7.9%, alone 38.3% 43.1%
β-blockers 10.9% 22.9% 42.9% 68.7% 22.0% 24.4% 29.3% 12.4%, alone 30.1%
Other 0.6% 7.4% 20.5% 54.2% 11.3% 14.4% 14.4% 13.1% 1.6%, alone
Page 78 of 91






























































For Peer Review Only
Supplementary Table S9. Study description and references.




CanPREDDICT s1 Canada 2008-2009 Adult patients with eGFR 15-45 ml/min from outpatient nephrology clinics Office BP measurement 95.3%
CKD-JAC s2 Japan 2007-2013 Patients aged 20-75 years with eGFR 10-59 ml/min from clinical centers
Mean of 3 BP measurements obtained 
according to a study protocol 92.1%
CKD-QLD s3 Australia 2011-2016 Adult CKD patients from renal practices in the public health system Office BP measurement 95.7%
CKD-REIN s4 France 2013-2016
Adult patients with eGFR <60 ml/min 
neither dialyzed nor transplanted from 
outpatient nephrology clinics
Office BP measurement at baseline visit 88.1%
CKDopps s5 Brazil, Germany, USA 2013-ongoing 
Adult patients with eGFR <60 ml/min 
neither dialyzed nor transplanted from 
outpatient nephrology clinics
Most recent office BP measurement in the 6 





CORE-CKD Thailand 2015-2017 Patients aged 18 or more, with CKD 3A-5 Mean of 3 BP measurements obtained according to a study protocol 87.2%
CRIC s6 USA 2003-2007 Patients aged 21-74 years with eGFR 20-70 ml/min from clinical centers
Mean of 3 BP measurements obtained 
according to a study protocol 98.5%
C-STRIDE s7 China 2011-2016 Patients aged 18-74 years with eGFR ≥ 15 ml/min from clinical centers
Mean of 3 BP measurements obtained 
according to a study protocol NA
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Supplementary Table S9. Study description and references (continued).
Study Country Recruitment 
years
Target population BP assessment Prevalence of 
treated 
hypertension
GCKD s8 Germany 2010-2012 Patients aged 18-74 years with eGFR ≥ 30 ml/min from outpatient nephrology clinics
Mean of 3 BP measurements obtained 
according to a study protocol NA
ICKD s9 India 2014-2015 Patients aged 18-70 years with eGFR ≥ 30 ml/min from outpatient nephrology clinics
Mean of 3 BP measurements obtained 
according to a study protocol NA
KNOW-CKD s10 South Korea 2011-2015
Patients aged 20-75 years with CKD 
stages 1-5 neither dialyzed nor 
transplanted from clinical centers
Office BP measurement obtained with 
automated device 94.6%
NRHP-Uruguay 
s11 Uruguay  2005-2016
Adult patients with CKD stages 1-5 either 
under nephrological care or referred to a 
nephrologist





2010-2017 Patients with type 2 diabetes treated in primary care
Office BP measurement obtained with either 
an automated or manual device NA
PSI BIND-NL s13 Netherlands 2010-2015 Adult patients with CKD 1-4 from outpatient nephrology clinics
Office BP measurement as reported by 
physician 92.0 %
RRID s14 UK 2008-2010 Adult patients with eGFR 30-59 ml/min from general practitioner surgeries
Mean of 3 BP measurements that differed by 
less than 10% obtained according to a study 
protocol
86.5%
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Supplementary Appendix S1. Variable dictionary.
Label Name (in statistical outputs) Definition Coding and covariate levels
Outcomes
Blood pressure (BP) 
control 1 ctrl_140
Binary variable indicating whether hypertensive participants had systolic 
BP <140 AND diastolic BP < 90 mm Hg at baseline. 
0 = BP ≥140 X 90
1 = BP <140 X 90
Blood pressure (BP) 
control 2 ctrl_130
Binary variable indicating whether hypertensive participants had systolic 
BP <130 AND diastolic BP < 80 mm Hg at baseline. 
0 = BP ≥130 X 80
1 = BP <130 X 80
Blood pressure (BP) 
control 3 ctrl_150
Binary variable indicating whether hypertensive participants had systolic 
BP <150 AND diastolic BP < 90 mm Hg at baseline in patients aged 60 
years or older.
0 = BP ≥150 X 90
1 = BP <150 X 90
Covariates
Age age2
Ag  in years is derived by subtracting the date of birth from the baseline 
visit date, rounded down to the nearest integer. This variable represents 
the categorical ordering of patients by age group as follows:
0 = 18 ≤ age < 65
1 = age ≥ 65
Gender female
This is a binary variable indicating self-defined sex, where participants 
were forced to pick their biological sex at birth: male or female
0 = Male
1 = Female
Educational attainment education This is a variable describing the education level attained as indicated by 
the participant at the baseline visit.
0 = ≤12 years of formal education
1 = >12 years of formal education
Diabetes diabetes
Diabetes is a binary variable indicating the history of diabetes at baseline. 
It includes serum fasting glucose ≥7.0 mmol/L (≥126 mg/dL), non-fasting 
glucose ≥11.1 mmol/L (≥200 mg/dL), glycated hemoglobin A1c ≥6.5%, 
and/or use of glucose lowering drugs.
0 = Without diabetes
1 = With diabetes
History of cardiovascular 
disease (CVD) cvd
CVD is a binary variable indicating self-reported cardiovascular disease. 
If the participant had coronary artery disease, prior revascularization, 
heart failure, stroke or peripheral vascular disease, then they have had a 
cardiovascular disease.
0 = Without CVD history
1 = With CVD history
Obesity obesity This is a binary variable indicating whether body mass index (BMI) is <30 kg/m² or ≥30 kg/m²
0= Not obese (BMI <30 kg/m²)
1= Obese (BMI ≥30 kg/m²)
Smoking status smoke This is a categorical variable indicating that the participant currently smokes cigarettes.
0 = Never or former smoker
1 = Current smoker
Page 83 of 91






























































For Peer Review Only
Label Name (in statistical outputs) Definition Coding and covariate levels
CKD stage egfr2 It is a categorical variable derived from non-missing eGFR calculated 
according to the CKD-EPI creatinine equation at baseline.
1 = 3A or 3B (30 ≤ eGFR <60)
2 = 4 or 5 (eGFR < 30)
Albuminuria categories ae3 Albuminuria or proteinuria, according to Table 7 from the KDIGO Guidelines 2012 
0 = Normal
(ACR <30 mg/g or 
AER <30 mg/24h or PCR <150 mg/g or
PER <150 mg/24h or Dipstick negative to 
trace)
1 = Mild
(30≤ ACR <300 mg/g or
30≤ AER <300 mg/24h or
150≤ PCR <500 mg/g or
150≤ PER<500 mg/24h or
Dipstick trace to +)
2 = Severe
(ACR ≥ 300 mg/g or
AER ≥ 300 mg/24h or
PCR ≥ 500 mg/g or
PER ≥ 500 mg/24h or
Dipstick + or greater)
Number of anti-
hypertensive drug classes n_drugs
Ordinal variable enumerating the number of anti-hypertensive drug 
classes prescribed at baseline (among diuretics, RAAS inhibitors, CCB, 
beta-blockers, and other)
0 = 0 drug class
1 = 1 drug class
2 = 2 drug classes
3 = 3 drug classes
4 = 4 or more drug classes
Diuretics diuretics Variable indicating whether diuretic therapy was prescribed 0 = No1= Yes
RAAS inhibitors raasi Variable indicating whether RAAS inhibitor therapy (either ACE inhibitors or ARBs) was prescribed
0 = No
1= Yes
Calcium channel blockers 
(CCB) ccb Variable indicating whether CCB therapy was prescribed
0 = No
1= Yes
Beta-blockers betab Variable indicating whether beta-blocker therapy was prescribed 0 = No1= Yes
Other anti-hypertensive 
classes other
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Supplementary Table S10. Missing covariates, by study.









CanPREDDICT 2411 0% 0% 0% 0% NA 0% 0% 0% NA 0% 0%
CKD-JAC 2686 1.4% 0% 0% 0% 16.1% 0% 0% 9.5% 15.0% 0% 8.4%
CKD-QLD 1674 0% 0% 0% NA NA 0% 0% 0% 8.5% 0% 1.2%
CKD-REIN 2626 2.5% 0% 0% 1.6% 1.5% 0.4% 1.7% 2.2% 0% 0% 11.1%
CKDopps BR 509 0% 0% 0% 0% 18.3% 0% 0.0% 45.8% 1.8% 0% 15.5%
CKDopps DE 877 0% 0% 0% NA NA 0% 0.1% 0.3% NA 0% 71.6%
CKDopps US 771 0% 0% 0% 1.2% 43.2% 0% 0.1% 9.7% 4.4% 0% 37.7%
CORE-CKD 758 0.1% 0% 0% 0% 0.1% 0% 0% 1.5% 0% 0% 0.8%
CRIC 2999 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 4.5%
CSTRIDE 1727 0% 0% 0% 0% 1.0% 5.8% 0.8% 7.4% 2.2% 0% 8.7%
GCKD 3909 0% 0% 0% 0% 0.1% 0% 0% 1.1% 0.3% 0% 0.2%
ICKD 702 3.4% 0% 0% 0% 0% 0% 0% 0.3% 0% 0% 0%
KNOW-CKD 1371 0.4% 0% 0% 0% 0.9% 0.5% 0% 1.1% 0.4% 0% 3.0%
NRHP-URU 12121 3.3% 0% 0% 9.1% NA 0% 0% 0% 0% 0% 0%
PROVALID 658 0% 0% 0% 0% NA 0% 0.9% 0% 10.8% 0% 1.7%
PSI BIND-NL 742 0% 0% 0% 8.1% 0.6% 12.9% 12.9% 1.1% 0.7% 0% 13.5%
RRID 1044 0% 0% 0% 0% 0.1% 0% 0% 0.1% 0% 0% 0%
Abbreviations: BP, blood pressure; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate. If missing values were more than 20% for covariates in a given 
cohort, these covariates were excluded from analyses.
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Supplementary Appendix S2. Acknowledgement and funding for collaborating cohorts. 
Study Acknowledgement and funding
CanPREDDICT CanPREDDICT was funded by an educational grant from Janssen-Ortho Inc.
CKD-JAC
We acknowledge the CKD-JAC data coordination center staff for their 
efforts to set up and validate analytical datasets for CKD-JAC: 
Masahiko Ando and Yoko Kubo. The CKD-JAC investigators and 
clinical sites, by region: Yoshio Taguma, Sendai Social Insurance 
Hospital (Miyagi); Yoshitaka Maeda, Toride Kyodo Hospital (Ibaragi); 
Eiji Kusano, Jichi Medical University (Tochigi); Kosaku Nitta, Tokyo 
Women’s Medical University Hospital (Tokyo); Yasuhiro Komatsu, St. 
Luke’s International Hospital (Tokyo); Tadao Akizawa, Showa 
University Hospital (Tokyo); Eriko Kinugasa, Showa University 
Yokohama Northern Hospital (Kanagawa); Ashio Yoshimura, Showa 
University Fujigaoka Hospital (Kanagawa); Hiroshige Ohashi, Gifu 
Prefectural General Medical Center (Gifu); Yuzo Watanabe, Kasugai 
Municipal Hospital (Aichi); Daijyo Inaguma, Kei Kurata, Tosei General 
Hospital (Aichi); Enyu Imai, Yoshitaka Isaka, Osaka University Hospital 
(Osaka); Yoshiharu Tsubakihara, Osaka General Medical Center 
(Osaka); Masahito Imanishi, Osaka City General Hospital (Osaka); 
Masaki Fukushima, Kurashiki Central Hospital (Okayama); Hideki 
Hirakata, Fukuoka Red Cross Hospital (Fukuoka); Kazuhito Takeda, 
Iizuka Hospital (Fukuoka).
CKD-JAC is funded by Kyowa-Hakko Kirin Co.Ltd, Tokyo, Japan and by 
the Japanese Society of Nephrology, Tokyo, Japan.
CKD-QLD
We acknowledge Dr Sree Krishna Venthurupalli, Dr Ken-Soon Tan and 
Mrs Anne Cameron for their contribution to the CKD-QLD study. CKD-
QLD is operated under the NHMRC CKD Centre of Research 
Excellence and Chronic Kidney Disease (CKD.CRE) in Queensland 
Research Collaborative. We thank the clinical and academic teams that 
are participating in this study and wholeheartedly thank all of the 
patients who are participating in the CKD.QLD Registry Study.
The study was supported from the National Health and Medical 
Research Council under the Centre of Research Excellence 
(APP1079502).
CKD-REIN
We acknowledge the CKD-REIN study coordination staff for their efforts 
in setting up the CKD-REIN cohort: Marie Metzger, Elodie Speyer, 
Céline Lange, Sophie Renault, Reine Ketchemin and all the clinical 
research associates. Clinical sites and investigators, by region: Alsace: 
Prs T. Hannedouche and B. Moulin (CHU, Strasbourg), Dr A. Klein (CH 
Colmar). Aquitaine: Pr C. Combe (CHU, Bordeaux), Dr J.P. Bourdenx 
(Clinique St Augustin, Bordeaux), Dr A. Keller, Dr C. Delclaux (CH, 
Libourne), Dr B. Vendrely (Clinique St Martin, Pessac), Dr B. Deroure 
(Clinique Delay, Bayonne), Dr A. Lacraz (CH, Bayonne). Basse 
Normandie: Dr T. Lobbedez (CHU, Caen), Dr I. Landru (CH, Lisieux). 
Ile de France: Pr Z. Massy (CHU, Boulogne – Billancourt), Pr P. Lang 
(CHU, Créteil), Dr X. Belenfant (CH, Montreuil), Pr E. Thervet (CHU, 
Paris), Dr P. Urena (Clinique du Landy, St Ouen), Dr M. Delahousse 
(Hôpital Foch, Suresnes). Languedoc – Roussillon: Dr C. Vela (CH, 
Perpignan). Limousin: Dr Danthu Clément (CHU, Limoges). Lorraine: Dr 
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H. Sekhri, Dr M. Smati (CH, Epinal), Dr M. Jamali, Dr B. Hacq (Clinique 
Louis Pasteur, Essey-les-Nancy), Dr V. Panescu, Dr M. Bellou 
(Polyclinique de Gentilly, Nancy), Pr Luc Frimat (CHU, Vandœuvre-les-
Nancy). Midi-Pyrénées: Pr N Kamar (CHU, Toulouse). Nord-Pas-de-
Calais: Prs C. Noël and F. Glowacki (CHU, Lille), Dr N. Maisonneuve 
(CH, Valenciennes), Dr R. Azar (CH, Dunkerque), Dr M. Hoffmann 
(Hôpital privé La Louvière, Lille). Pays-de-la Loire: Pr M. Hourmant 
(CHU, Nantes), Dr A. Testa (Centre de dialyse, Rezé), Dr D. Besnier 
(CH, St Nazaire). Picardie: Pr G. Choukroun (CHU, Amiens), Dr G. 
Lambrey (CH, Beauvais). Provence-Alpes - Côte d’Azur: Pr S. Burtey 
(CHU, Marseille), Dr G. Lebrun (CH, Aix-en-Provence), Dr E. Magnant 
(Polyclinique du Parc Rambot, Aix-en-Provence). Rhône-Alpes: Pr M. 
Laville, Pr D. Fouque (CHU, Lyon-Sud) and L. Juillard (CHU Edouard 
Herriot, Lyon), Dr C. Chazot (Centre de rein artificiel Tassin Charcot, 
Ste Foy-les-Lyon), Pr P. Zaoui (CHU, Grenoble), Dr F. Kuentz (Centre 
de santé rénale, Grenoble).
CKD-REIN is funded by the Agence Nationale de la Recherche through 
the 2010 «Cohortes-Investissements d’Avenir » program and by the 
2010 national Programme Hospitalier de Recherche Clinique. CKD-
REIN is also supported through a public-private partnership with 
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1





(a) Indicate the study’s design with a commonly used term in the title 
or the abstract
2Title and abstract 1
(b) Provide in the abstract an informative and balanced summary of 
what was done and what was found
2
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation 
being reported
3-4
Objectives 3 State specific objectives, including any prespecified hypotheses 4
Methods
Study design 4 Present key elements of study design early in the paper 4, 14
Setting 5 Describe the setting, locations, and relevant dates, including periods 
of recruitment, exposure, follow-up, and data collection
14, S6-7
Participants 6 (a) Give the eligibility criteria, and the sources and methods of 
selection of participants
14
Variables 7 Clearly define all outcomes, exposures, predictors, potential 





8*  For each variable of interest, give sources of data and details of 
methods of assessment (measurement). Describe comparability of 
assessment methods if there is more than one group
14, S6-7
Bias 9 Describe any efforts to address potential sources of bias 15
Study size 10 Explain how the study size was arrived at 14
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If 
applicable, describe which groupings were chosen and why
14
(a) Describe all statistical methods, including those used to control for 
confounding
15-16
(b) Describe any methods used to examine subgroups and interactions 15-16
(c) Explain how missing data were addressed 15-16
(d) If applicable, describe analytical methods taking account of 
sampling strategy
Statistical methods 12
(e) Describe any sensitivity analyses 15-16
Results
(a) Report numbers of individuals at each stage of study—eg numbers 
potentially eligible, examined for eligibility, confirmed eligible, 
included in the study, completing follow-up, and analysed
S8
(b) Give reasons for non-participation at each stage S8
Participants 13*
(c) Consider use of a flow diagram -
(a) Give characteristics of study participants (eg demographic, 
clinical, social) and information on exposures and potential 
confounders
24Descriptive data 14*
(b) Indicate number of participants with missing data for each variable 
of interest
S8
Outcome data 15* Report numbers of outcome events or summary measures 25
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2
(a) Give unadjusted estimates and, if applicable, confounder-adjusted 
estimates and their precision (eg, 95% confidence interval). Make 











(c) If relevant, consider translating estimates of relative risk into 
absolute risk for a meaningful time period
-
Other analyses 17 Report other analyses done—eg analyses of subgroups and 
interactions, and sensitivity analyses
6, S9-14
Discussion
Key results 18 Summarise key results with reference to study objectives 8
Limitations 19 Discuss limitations of the study, taking into account sources of 
potential bias or imprecision. Discuss both direction and magnitude of 
any potential bias
11-12
Interpretation 20 Give a cautious overall interpretation of results considering 
objectives, limitations, multiplicity of analyses, results from similar 
studies, and other relevant evidence
12
Generalisability 21 Discuss the generalisability (external validity) of the study results 12
Other information
Funding 22 Give the source of funding and the role of the funders for the present 
study and, if applicable, for the original study on which the present 
article is based
17, S2-5
*Give information separately for exposed and unexposed groups.
Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and 
published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely 
available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at 
http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is 
available at www.strobe-statement.org.
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CONCLUSION:
International variations in blood pressure control and 
antihypertensive prescription patterns in chronic kidney disease
Substantial worldwide variation in 
hypertension control exists. Heterogeneity in 
prescription patterns calls for further 
investigation into the impact on patient 
outcomes.
Alencar de Pinho et al, 2019
34 602 individuals with eGFR <60 ml/min/1.73m² and treated 
hypertension across 17 cohort studies in 4 continents
Better BP control Worse BP control
Prescription pattern of antihypertensive drug classes across cohorts 
RAAS inhibitors: 54 to 91%; diuretics: 11% to 79%; beta-blockers: 22% to 
70%; calcium-channel blockers: 27% to 75%.
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